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Abstract 
 
Amir Aghajanian: A novel role for reactive oxygen species in the regulation of 
RhoA; implications for endothelial permeability and leukocyte transmigration. 
(Under the direction of Keith Burridge, PhD) 
 
 
The endothelial lining of the vasculature plays a critical role in regulating 
the passage of fluid, macromolecules, and cells between the blood and 
surrounding tissues. Vascular permeability is tightly regulated and is modulated 
during both physiological and pathological situations. Our laboratory is interested 
in the mechanisms which regulate vascular permeability and the transmigration 
of leukocytes during inflammation. The migration of leukocytes across the 
endothelial barrier is called “leukocyte transendothelial migration” (TEM). 
Deciphering the mechanisms which regulate TEM is important to understanding 
and managing inflammatory diseases.
My interest in TEM is focused on pathways which involve small GTPases. 
My specific interest is in the role of Rho GTPases and their regulation by reactive 
oxygen species (ROS) during leukocyte TEM. Although ROS have been largely 
seen as mediators of oxidative damage, more recently, ROS have been 
recognized as necessary components of cell signaling pathways. Importantly, 
ROS have been shown to play an important role in regulating vascular 
permeability and TEM.  
 iv 
In this dissertation, I show that physiological levels of ROS can directly 
activate RhoA in cells. In vitro studies had previously identified two critical 
cysteine residues in the nucleotide binding pocket of RhoA that are oxidatively 
modified by ROS. My work showed that this oxidative regulation of RhoA can 
occur in a cellular context. Before these studies, the regulation of small GTPases 
had almost exclusively focused on regulatory proteins. Importantly, my work 
identifies direct oxidative modification as a novel way to regulate RhoA activity.  
I extended this work by investigating the regulation of RhoA by ROS in the 
context of leukocyte TEM. Based on these findings and my previous work, I 
hypothesized that leukocyte adhesion to endothelial cells initiates ROS 
generation and the direct activation of RhoA to promote leukocyte TEM. In 
preliminary studies, I found that crosslinking of a cell adhesion molecule (ICAM-
1) stimulates RhoA and Rac1 activation. In addition the activation of RhoA 
appears to be dependent on ROS, as seen by studies of redox-insensitive 
mutants. The work presented in this dissertation lays the framework for future 
studies on the role of ROS during leukocyte adhesion and TEM. 
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Chapter 1: Introduction 
Endothelial cell-cell junctions 
The vascular system is a network of vessels that serve as conduits for the 
transport of nutrients, macromolecules and blood cells throughout the body.  The 
luminal layer of the blood vessel wall consists of a single sheet of endothelial 
cells (ECs) which provide the primary physical barrier between the blood and 
underlying tissues.  Cell junctions linking adjacent ECs are important regulators 
of the permeability characteristics of the endothelium and are modulated to allow 
selective and specific passage of blood cells and macromolecules.  Opening and 
resealing of the junctional barrier must occur during normal physiological 
processes such as immune surveillance, antigen recognition, and acute 
inflammatory responses. 
Conversely, misregulation of cell junctions can lead to pathological 
situations, including many chronic inflammatory diseases and edema.  As such, 
the endothelium and its junctions play a critical role in regulating vascular 
function during both physiological and pathological processes.  Vascular 
permeability is the sum of many mechanisms which either increase or decrease 
barrier function [1, 2].  In this introduction, I will focus on those pathways which 
mediate reversible, transient increases in permeability due to junctional 
disruption. 
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Vascular barrier function is not only differentially modulated in response to 
physiological stimuli within a given vessel, but additionally, different vascular 
beds have unique permeability and barrier characteristics due to 
morphologicallyheterogeneous endothelial junctions [3].  At two extremes of the 
continuum are the relatively impermeable endothelium forming the blood brain 
barrier, and the high endothelial venules which are sites of constitutive leukocyte 
transendothelial migration (TEM).  
Regulation of EC junctions, and by extension, vascular permeability is 
provided by a variety of signaling cues.  These signals function to promote 
normal homeostasis but are also involved in pathological changes in 
permeability.  In this introduction I will discuss regulation of EC junctions, first in 
the context of permeability to fluid and small macromolecules; and second how 
these junctions are modified to allow leukocyte TEM during inflammation.  
Common pathways responsible for regulation of junctional permeability exist 
despite differences in the initiating signaling event.  These pathways converge to 
increase junctional permeability by a variety of mechanisms. 
Tight Junctions 
Compared to the well-developed and spatially distinct tight junctions (TJs) 
of epithelial cells, in ECs TJs are less structured and more intermixed with the 
adherens junctions.  Membrane-spanning junctional proteins contain extracellular 
domains for adhesion via homophilic interactions with adjacent cells, forming a 
physical barrier. Occludin was the first transmembrane protein to be identified at 
the TJs of both epithelia and endothelia [4].  Numerous lines of evidence point to 
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a central role for occludin in regulating paracellular permeability of blood vessels 
[5].  The claudin family of transmembrane proteins are also a major component 
of TJs.  The over 20 proteins which make up the claudin family have a wide 
distribution, although claudin-5 appears to be specific to ECs [6].  The junctional 
adhesion molecule (JAM) proteins uniquely contribute to endothelial permeability 
because they can participate directly in barrier function, but can also act as 
receptors that interact with leukocyte integrins to regulate and direct leukocyte 
transmigration.  Furthermore, the heterogeneity of EC junctions is reflected by 
differential expression of specific JAM isoforms (reviewed in Weber et al., 2007) 
[7].  In addition to these transmembrane proteins, there are also proteins that 
form a complex on the cytoplasmic face of the TJ, including ZO-1 and ZO-2.  
These scaffold proteins link the cytoplasmic domains of the transmembrane 
proteins to the actin cytoskeleton [8], as illustrated in Figure 1. 
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Figure 1. Intercellular interactions between endothelial cells and leukocytes. Tight junctions 
and adherens junctions are intermixed along the lateral surface of ECs. Extracellular domains of 
occludin, claudins, and JAM proteins form homophilic interactions to create tight junctions. The 
intracellular domains of these proteins associate with the actin cytoskeleton through ZO proteins 
(ZO-1/ZO-2) and other components (not shown). The major transmembrane component of 
adherens junctions is VE-cadherin. The cytoplasmic domain associates with the cytoskeleton via 
α and β-catenin and likely other unidentified components (X). p120 catenin serves a supporting 
role to maintain stability of the cadherin complex. Adhesive interactions between ECs and 
leukocytes occurs via glycoprotein ligands on the surface of leukocytes and selectins expressed 
by ECs. In addition, integrins expressed by leukocytes interact with cell adhesion molecules 
expressed by ECs (ICAM and VCAM). 
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Adherens Junctions 
ECs also contain adherens junctions (AJs), which mediate strong 
adhesion between adjacent cells predominantly via the transmembrane protein 
VE-cadherin.    The importance of VE-cadherin for barrier maintenance in ECs is 
underscored by the observation that injection of VE-cadherin function-blocking 
antibodies induces neutrophil infiltration in an in vivo peritonitis model [9], and 
vascular hyper-permeability in lung interstitium [10]. The intracellular domain of 
VE-cadherin binds to cytoplasmic AJ-associated proteins, particularly the 
catenins: α-, β-, and p120 catenin.  Since their discovery, α- and β- catenin have 
been considered as critical linkages between cadherin cytoplasmic domains and 
the actin cytoskeleton.  However, the dogma that this is a stable, quaternary 
interaction has been challenged by experiments showing that α-catenin cannot 
interact simultaneously with the cadherin/β-catenin complex and F-actin [11], 
indicating that linkage to actin may require other components [12].  Finally, p120 
catenin is important during barrier maintenance, not by acting as a link to the 
actin cytoskeleton, but by regulating the stability of the cadherin complex, 
maintaining VE-cadherin’s surface expression [13].   
Actin Cytoskeleton 
 Many studies have shown that an interaction with the actin cytoskeleton is 
required for EC junctional integrity to anchor and reinforce junctions in ECs [14, 
15].  Actin-based structures in the cell periphery (cortical actin bundles) are 
thought to promote junctional stability and barrier function [15].  Conversely, 
under conditions of increased permeability and junctional instability, cortical actin 
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bundles become less prominent and induction of cytoplasmic stress fibers 
occurs.  Tension imparted by these stress fibers on junctions is thought to 
provide a mechanism for increasing permeability [16]. The formation of these 
actin structures is largely regulated by Rho family GTPases, as discussed below.   
Mechanisms regulating vascular permeability 
Vasoactive compounds such as thrombin, histamine and vascular 
endothelial growth factor (VEGF) can regulate endothelial junctions by multiple 
mechanisms.  They can alter the architecture of the endothelial cleft by affecting 
junctional protein expression, localization and stability. Sometimes this occurs via 
protein phosphorylation.  They may also activate downstream signaling pathways 
such as the production of reactive oxygen species (ROS) and alter the activity of 
Rho and Rac small GTPases, leading to changes impacting the cytoskeleton.  
Expression and Stability of Junctional Proteins 
 There are several examples where loss of a junctional protein has been 
demonstrated to negatively impact barrier function.  For example, loss of claudin-
5 leaves morphologically normal blood vessels, but they become selectively 
permeable to small molecules [17].  In certain physiological instances, exposure 
to vasoactive compounds also causes loss of a junctional protein.  For instance, 
histamine markedly reduces ZO-1 expression in cultured retinal ECs [18].  VEGF 
increases brain microvascular EC permeability by affecting occludin and ZO-1 
localization at TJs, and decreasing levels of occludin expression [19].  In some 
situations, junctional components may be removed by proteolysis.  For example, 
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the cytokine TGF-β upgregulates expression of matrix metalloprotease-9 (MMP-
9), which results in subsequent degradation of occludin in retinal ECs [20]. 
 One final illustration of the need for appropriate expression of junction 
components is provided by the interplay between p120 catenin and VE-cadherin 
stability and surface expression.  Xiao and colleagues demonstrated that p120 
catenin is required for stability and regulation of cellular VE-cadherin content [13].  
Reducing levels of p120 catenin caused a dramatic dose-dependent reduction of 
VE-cadherin in the cell.  In contrast, overexpression of p120 catenin increased 
surface expression of VE-cadherin by inhibiting endocytosis and endosomal 
degradation of cell surface VE-cadherin.  Subsequent work confirmed that the 
interaction of p120 with VE-cadherin is required for the maintenance of 
endothelial barrier function [21].  This and earlier observations that vasoactive 
compounds such as thrombin can alter p120 catenin phosphorylation [22], 
suggest a mechanism linking p120 phosphorylation status, association with VE-
cadherin, and destabilization of endothelial barrier function. 
Protein phosphorylation and dephosphorylation 
 Phosphorylation is a common post-translational modification for regulating 
intracellular signaling.  The importance of tightly regulating junctional protein 
phosphorylation is underscored by the observation that certain phosphatases 
constitutively associate with cell-cell junctions in quiescent ECs, presumably to 
maintain the low level of phosphorylation required for junctional integrity [22]. 
 Occludin phosphorylation is a major mechanism for regulating TJ 
permeability.  VEGF induces rapid phosphorylation of occludin and ZO-1 under 
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conditions where permeability is also increased [23].  However, there are also 
observations that show in vitro VEGF treatment leaves junctions morphologically 
intact, suggesting that VEGF enhances transcellular permeability [24].  
Therefore, regulation of EC permeability by VEGF is complex and possibly 
involves two or more distinct modes of permeability.  Other vasoactive 
compounds such as histamine and lysophosphatidic acid (LPA) also induce 
phosphorylation of occludin in EC lines [25].  While these studies linked 
phosphorylation of occludin with increased vascular permeability, a recent study 
proposed that occludin dephosphorylation may also decrease permeability [26].  
This might indicate that phosphorylation at particular residues either promotes or 
inhibits permeability, and that a basal level of phosphorylation on specific 
residues may be required for occludin’s barrier enhancing role.   
  Numerous studies have demonstrated the role of tyrosine 
phosphorylation of AJ proteins in AJ disassembly [27, 28].  The catenins are 
frequent targets of phosphorylation, which promotes their disassociation from 
VE-cadherin.  ECs lacking the adhesion protein PECAM-1 have elevated levels 
of tyrosine-phosphorylated β-catenin, constitutive association of this pool with 
activated GSK-3β, and a resulting increase in proteasomal degradation of β-
catenin [29].  A model was suggested in which tyrosine phosphorylation of 
PECAM-1 enables it to act as a scaffold, promoting recruitment of both the 
phosphatase SHP-2 and phosphorylated β-catenin.  This facilitates 
dephosphorylation of β-catenin, allowing it to bind to VE-cadherin and thus 
promoting AJ complex reassembly [29]. 
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VE-cadherin itself is also a target for phosphorylation downstream of 
vasoactive agents.  Phosphorylation on two tyrosine residues present on the 
cytoplasmic C-terminal region of VE-cadherin, Y658 and Y731, was found to be 
critical to the binding of p120- and β-catenin respectively to this region [30].  
Furthermore, expression of phospho-mimetic VE-cadherin mutants in an artificial 
cell system (CHO cells) resulted in increased permeability to HRP-IgG.  
However, another residue (Y685) has been recently discovered to be 
phosphorylated by Src [31].  In this second study, treatment with VEGF was the 
stimulus, so it is possible that different tyrosines are phosphorylated in different 
conditions.  Adding another layer of complexity, VE-cadherin can also be 
phosphorylated on serine residues.  Gavard and colleagues found that Ser665 is 
phosphorylated by p21-activated kinase (PAK) upon VEGF treatment and this 
results in β-arrestin-dependent endocytosis of VE-cadherin and promotion of EC 
permeability [32].  The process is initiated by Src-dependent phosphorylation and 
activation of the Rac1 GEF Vav2, followed by Rac1-mediated activation of its 
downstream effector PAK. 
Rho GTPases 
Rho GTPases, particularly RhoA, Rac1, and Cdc42 have a long history of 
being implicated in cytoskeleton regulation [33].  In the context of ECs, Rho 
signaling regulates cell junctions and vascular permeability by influencing actin 
cytoskeleton dynamics [16].  In turn, engagement of adhesion proteins influences 
activity of the GTPases, providing a two-way feedback mechanism [34, 35].  
Although this thesis focuses on RhoA and Rac1 signaling, it should be mentioned 
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that Cdc42 has also been shown to have a role in regulating vascular 
permeability by promoting the reassembly of AJs [36].  
The development of isometric tension in ECs has been suggested as a 
primary mechanism of regulating endothelial barrier function [37].  Very often, 
agents that increase vascular permeability also activate RhoA.  In turn, active 
RhoA stimulates Rho kinase which leads to actomyosin contractility by promoting 
the phosphorylation of myosin light chain (MLC) directly or indirectly through 
inhibition of MLC phosphatase [33].  This contractility drives the formation of 
stress fibers and assembly of focal adhesions [38].  Rho-mediated contractility 
has been suggested to be a primary mechanism leading to increased 
permeability downstream of thrombin binding [39].  It should be noted, however, 
that Rho kinase also phosphorylates occludin and claudin-5, affecting their 
functions [40]. 
 The case for Rac GTPase is much more controversial.  Whereas activated 
Rac1 enhances cell–cell adhesion in epithelial cells [41], in ECs the situation is 
contradictory.  The earliest data showed that both dominant negative and 
constitutively active Rac induced permeability, consistent with the level of Rac 
needing to be finely tuned for optimal junctional integrity [42].  Others have also 
demonstrated that activation of Rac, for example in response to sphingosine-1-
phosphate, promoted cortical actin rearrangement and enhanced barrier function 
in EC monolayers [43, 44].  However, other groups have shown the opposite, 
with Rac activation causing increased permeability [32, 45].  VEGF treatment 
produced a similar effect, where downstream activation of the Rac effector PAK 
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induced VE-cadherin serine phosphorylation and endocytosis, leading to 
junctional disruption [32].  PAK family kinase activity downstream from Rac 
signaling can also stimulate opening of cell junctions by direct phosphorylation of 
MLC and subsequent induction of actomyosin contractility [46].  That active Rac 
in some situations increases permeability but in others decreases permeability, 
suggests that the input signal may be critical and that different scaffolding 
proteins may direct Rac signaling pathways in seemingly opposite directions. 
Reactive Oxygen Species 
 Historically, ROS have been studied in the context of pathogen killing by 
phagocytic cells of the immune system, and as potentially harmful by-products of 
aerobic metabolism.  However, more recently ROS have been recognized as 
important components of cell signaling pathways [47].   
Numerous studies have shown that ROS can increase endothelial 
permeability both in vitro and in vivo, and this permeability can be inhibited by 
antioxidants and free radical scavengers [48].  Interestingly, Rac1 is a major 
component of the vascular NADPH oxidase complex [49].  Expression of 
constitutively active Rac1 resulted in ROS production concomitant with disruption 
of VE-cadherin at cell-cell junctions, tyrosine phosphorylation of α-catenin, and 
ultimately increased permeability [45].  It is now known that Rac-mediated ROS 
production leads to activation of the tyrosine kinase Pyk2, which subsequently 
phosphorylates β-catenin and thus destabilizes the AJ [50].  ROS generation also 
occurs downstream from a variety of vasoactive factors, notably VEGF.  
Recently, it was confirmed that VEGF-induced junctional disruption and ROS 
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production similarly involves Rac1 activation [49]. Moreover, VEGF-induced Rac 
activation requires VEGFR-2, active Src, subsequent activation of the guanine 
nucleotide exchange factor Vav2, and finally activation of Rac1 [51]. This 
pathway was shown to directly affect the phosphorylation of VE-cadherin and β-
catenin in a ROS dependent manner, thereby affecting adherens junction stability 
and endothelial permeability [52]. Therefore, production of ROS downstream of 
Rac in this pathway is one mechanism of inducing EC permeability, although 
other ROS-independent pathways have also been suggested [32, 53].  
One of the mechanisms by which ROS could alter vascular permeability 
involves regulation of junctional protein phosphorylation, which as discussed 
earlier, is often associated with increased permeability.  ROS can strongly 
inactivate protein phosphatases by oxidation of a critical cysteine residue in the 
catalytic site [54].  The prevalence of phosphatases (VE-PTP, DEP-1, PTPµ, 
SHP-2) at EC junctions suggests they are critical for maintaining the low basal 
phosphorylation levels conducive for junctional integrity [55].  Localized 
production of ROS and inactivation of phosphatases at these sites would 
therefore contribute to elevated phosphorylation and junctional disruption.  
Regulation of Rho GTPases by ROS 
 ROS may also regulate junctional permeability by affecting the 
organization  of the actin cytoskeleton [56].  This raises the intriguing possibility 
that ROS may regulate GTPase activity. A number of reports have shown 
indirectly that ROS can affect GTPase activity. The first major observation was 
made in by Nimnual et al., in which it was shown that ROS generation 
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downstream of active Rac1 (presumably through NADPH oxidase) results in 
decreased RhoA activity [57]. This “Bar-sagi pathway” involves ROS-mediated 
inactivation of a tyrosine phosphatase, leading to elevated p190 Rho GAP 
activity and therefore decreased RhoA activity. This observation that elevated 
Rac1 activity can lead to decreased RhoA activity has been made before, 
although not in the context of ROS [58]. Similar findings were made in the 
context of ROS by Wojciak-Stothard et al., who measured RhoA and Rac1 
activities in pulmonary aortic endothelial cells under conditions of hypoxia [59]. 
Hypoxia was shown to induce a gradual decrease in Rac1 activity, and an 
increase in RhoA activity. Interestingly, hypoxia was also shown to result in 
decreased ROS production, thereby, potentially implicating ROS as an indirect 
mediator of GTPase activity. More recently, a novel activator of NADPH oxidase 
(Nox4) called Poldip2 was found to stimulate ROS production, RhoA activation, 
and stress fiber formation in vascular smooth muscle cells [60].  
 Although these studies do indicate that ROS could be a mediator of RhoA 
activity, it is critical to note that they do not show a direct effect of ROS on RhoA. 
There is considerable evidence that ROS are capable of directly regulating Rac1 
and RhoA by cysteine oxidation. Work on the regulation of GTPases by ROS and 
RNS actually began with studies of Ras in which treatment of T-cells with nitric 
oxide gas resulted in GDP/GTP exchange and an increase in the pool of Ras-
GTP [61]. It was later found that NO treatment caused an oxidation of cysteine 
118 which was responsible for nucleotide exchange and subsequent Ras 
activation [62]. 
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 This work was later extended to include Rho GTPases, specifically Rac1 
and RhoA. It was found that a subset of Rho GTPases contain a novel, 
conserved motif (GXXXXGK(S/T)C) that is critical for regulation by ROS and RNS 
[63]. In Rac1, this motif contains cysteine 18. RhoA is interesting in that two 
cysteines occur within the conserved motif (cysteine 16 and cysteine 20). This 
raises the intriguing possibility that oxidation could result in formation of an 
intramolecular disulfide bond, which could affect GTPase activity. The formation 
of a disulfide bond was in fact observed, when recombinant, purified RhoA 
protein was exposed to NO radical [64]. This led to decreased nucleotide 
exchange, which could be reversed by addition of reducing agent (GSH). 
Although high levels of oxidants could result in disulfide bond formation, it was 
hypothesized that low levels of ROS could result in activation of RhoA due to 
radical mediated exchange of GDP for GTP. The studies described in Chapter 2 
are based on this hypothesis, that ROS generation in cells can directly affect 
RhoA activity.   
Leukocyte TEM 
The regulated transmigration of leukocytes across the endothelial lining of 
the vasculature is critical to the inflammatory response.  However, when TEM is 
excessive or inappropriately localized, it can initiate many pathological 
processes.  For example, the transmigration of leukocytes is an early step in the 
development of atherosclerotic plaques [65].  Also, the pathogenesis of multiple 
sclerosis involves a massive influx of leukocytes transmigrating into the brain, 
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leading to tissue damage and neurological disability [66]. Numerous chronic 
inflammatory diseases such as arthritis also involve TEM. 
The process of leukocyte TEM is carefully coordinated by a large number 
of different adhesion molecules expressed on the surface of endothelial cells. 
Most adhesion molecules are expressed at low basal levels in resting endothelial 
cells, however, the inflammatory response causes activation of endothelial cells 
and subsequently increased expression of adhesion molecules. These adhesion 
molecules interact with ligands expressed on the surface of leukocytes. Although 
it is likely that each type of leukocyte utilizes unique mechanisms to mediate 
TEM it is generally accepted that leukocytes follow a general, stepwise process 
of adhesion and TEM.  
Steps in TEM 
Leukocyte adhesion and TEM occurs in sequential steps, each of which 
initiates signaling that facilitates progression to the next step [67, 68]. The 
process begins with the capture of leukocytes on ECs at sites of inflammation. 
This capture is largely mediated by weak interactions between selectins on the 
surface of endothelial cells and a variety of glycosylated ligands on the surface of 
leukocytes, such as CD44, PSGL-1, and ESL1. Interestingly, although the 
interaction between selectins and their ligands is relatively weak, a threshold 
level of shear stress is required for efficient binding [69, 70]. As leukocytes roll 
along the vessel wall, chemokines expressed by activated endothelial cells result 
in activation of integrins on the leukocyte surface. Importantly, cytokines regulate 
a positive feedback loop which promotes the production of more adhesion 
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molecules and cytokines. Activated integrins serve as ligands for the cell 
adhesion molecules, ICAM-1 and VCAM-1. MAC-1 and LFA-1 are ligands for 
ICAM-1, and VLA-4 is a ligand for VCAM-1 (described in detail below). 
Interestingly, it has been recently reported that E-selectin binding to its leukocyte 
ligand PSGL-1 promotes the activation of LFA-1, thereby promoting slow 
leukocyte rolling [71]. This is yet another example of how initial steps in the 
adhesion and transmigration process directly promote subsequent steps. 
Although ICAM-1 and VCAM-1 support rolling, they are best described in their 
role of mediating firm adhesion of leukocytes to the endothelial surface. Firm 
adhesion allows leukocytes to spread and begin to migrate along the vessel wall, 
prior to diapedesis. This process of intraluminal crawling is thought to be critical 
for efficient TEM, as it allows the leukocyte to find the “optimal” site to undergo 
diapedesis [72]. Interestingly, it has been found that ICAM-1 and one of its 
integrin ligands (MAC-1) are critical for this process [73].  
When the leukocyte has reached an appropriate site, diapedesis can 
occur by either of two routes; the most prevalent mechanism in vitro is 
“paracellular” TEM, which requires transient junctional disruption as leukocytes 
migrate between adjacent cells. It appears that tricellular junctions may be 
preferential for paracellular transmigration due to their unique composition of 
discontinuous tight junctions and overlaying “flaps” [74]. Neutrophils seem to 
prefer these unique junctions in vitro under flow [75]. More recently, in vivo 
experiments have corroborated these in vitro findings and extended them to 
include a role for ICAM-1 enrichment at tricellular junctions [76]. TEM can also 
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occur by a “transcellular” route in which a leukocyte moves through the body of 
an EC, probably via the transient formation of a pore. Transcellular TEM has 
been reported in vitro and in vivo [77]. The factors which determine the “optimal” 
site for diapedesis and the route which is taken (paracellular vs transcellular) are 
still largely unknown. Common to both routes is the formation of a transmigratory 
“docking structure” which extends from the endothelium to surround the adherent 
leukocyte prior to the onset of diapedesis. The signaling mechanisms involved in 
formation of these structures and subsequently the completion of transmigration 
are discussed below.  
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Figure 2. Leukocyte adhesion and transmigration cascade. Model illustrating the main steps 
in leukocyte TEM and the  endothelial adhesion molecules and corresponding leukocyte ligands 
involved.  
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ICAM-1 
Intercellular adhesion molecule 1 (ICAM-1) and vascular endothelial cell 
adhesion molecule 1 (VCAM-1) are particularly important for firm, integrin-
mediated adhesion of leukocytes to ECs and subsequent TEM [78].  The role of 
these cell adhesion molecules (CAMs) has been extensively reviewed [79]. 
ICAM-1 is a member of the Ig-like superfamily of proteins, with 5 Ig like repeats in 
its extracellular domain and a short cytoplasmic tail [80].  In vitro, ICAM-1 is 
expressed constitutively on the surface of endothelial cells, albeit at low levels, 
however stimulation with IL-1B or TNF-alpha for 12-24 hrs can enhance surface 
expression by 40 times [81]. Interestingly, the increase in expression of ICAM-1 
corresponds to downregulation of E-selectin expression. The importance of 
ICAM-1-mediated signaling to transendothelial migration is demonstrated by the 
deficient immune response exhibited by ICAM-1-null mice [82].  Furthermore, 
antibody blockade of ICAM-1 inhibits leukocyte TEM in vivo [83] and in vitro. 
Additionally, both the expression of ICAM-1 [84] and the activation of ICAM-
signaling by crosslinking [82] have been shown to increase vascular permeability 
in vitro. The importance of ICAM’s cytoplasmic tail has been demonstrated in 
vitro, in experiments using reconstituted cell lines. Sans et al. showed that 
expression of ICAM-1 in CHO cells, which don’t express any endogenous cell 
adhesion molecules, significantly enhances neutrophil transmigration [85]. 
However, this effect was abolished when cells expressed a cytoplasmic tail-
deleted mutant of ICAM-1. These results indicate that ICAM-1 alone can support 
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TEM and that this requires the interaction of ICAM-1’s cytoplasmic tail with other 
proteins which are required for TEM. 
VCAM-1 
Similar to studies of ICAM-1, blocking VCAM signaling with function 
blocking antibodies against VCAM-1 or its integrin ligand VLA-4 inhibits leukocyte 
adhesion to ECs and decreases TEM, although not as significantly as blocking 
both ICAM1 and VCAM [86]. However, unlike ICAM, whose integrin ligands are 
expressed by all leukocytes including neutrophils, VCAM’s integrin ligand (VLA-
4) is not expressed on neutrophils [87].  
 Although VCAM may not contribute significantly to early stages of acute 
inflammation, which is mediated largely by neutrophils, it does play significant 
roles in chronic inflammation particularly atherosclerosis. Atherosclerosis is a 
chronic inflammatory condition, whose initial stages are mediated primarily by 
monocytes. This is reflected in observations that VCAM is the first adhesion 
molecule expressed prior to atherosclerotic plaque development [88]. In vivo 
models of carotid injury and atherosclerosis, have shown that anti-VCAM 
antibodies prevent monocyte adhesion [89] and that neointimal formation can be 
reduced by administration of anti-VLA4 antibodies [90] or siRNA knockdown of 
VCAM [91].  
Signaling downstream of ICAM and VCAM 
Figure 3 illustrates three potential mechanisms downstream of VCAM-1 
and ICAM-1 engagement which lead to paracellular TEM of leukocytes: Rho 
GTPase signaling, ROS-mediated regulation, and tyrosine phosphorylation of 
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junctional components. These diverse signals, involving numerous pathways are 
discussed below. 
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Figure 3. Signals from endothelial ICAM-1 and VCAM-1 which affect endothelial barrier 
function during TEM. Signals downstream of ICAM (solid lines) and VCAM-1 (dotted lines) are 
unique, but overlap extensively. A yet undetermined pathway from ROS/RNS to Rho GTPases is 
yet to be determined, and will be discussed in Chapter 3. 
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Rho GTPases 
One well-studied outcome of ICAM-engagement is RhoA activation.  
Artificially simulating leukocyte adhesion by crosslinking ICAM-1 with antibodies 
results in stress fiber formation downstream of Rho GTP-loading [92, 93].  By 
using C3 transferase, a bacterially-derived Rho inhibitor, Adamson and 
colleagues showed that ICAM-1-stimulated cytoskeletal rearrangements required 
for efficient T-lymphocyte TEM were dependent on RhoA activation [94].  
Treatment of ECs with Y-27632, an inhibitor of Rho kinase, or inhibitors of 
myosin light chain kinase also reduced neutrophil TEM [95, 96].  Our laboratory 
has recently shown that ICAM-1 engagement also activates RhoG [97].  This 
activation was critical for formation of the apical membrane protrusions which 
extend from ECs to partially engulf adherent leukocytes. These “docking 
structures” may facilitate the development of leukocyte pseudopods which extend 
through EC junctions [98]. Depletion of endothelial RhoG decreased cup 
formation and also inhibited leukocyte TEM.  Further investigation revealed that 
the cytoplasmic tail of ICAM-1 binds SGEF, a RhoG guanine nucleotide 
exchange factor (GEF), which provides a mechanism of RhoG activation 
downstream of ICAM-1. 
VCAM-1 has also been placed upstream of Rho family GTPases.  
Antibody-mediated VCAM-1 crosslinking on HUVECs results in activation of 
Rac1, induction of stress fibers, and formation of gaps in the EC monolayer 
leading to a decrease in electrical resistance [99].  The junctional disorganization 
induced by VCAM-1 engagement was dependent on ROS production. The role of 
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VCAM in production of ROS through Rac1 activation is discussed below. In 
addition to ICAM-1, VCAM-1 is also present in the cup-like docking structures 
which form at the site of leukocyte-EC interaction [100, 101]. However the role of 
VCAM in these structures has not been fully investigated. 
Reactive Oxygen Species 
 ROS have been implicated as an important mechanism regulating 
leukocyte TEM.  Endothelial ROS production upon adhesion of neutrophils has 
been shown to mediate cytoskeletal changes and cellular stiffening of endothelial 
cells to promote TEM [100]. Importantly, ICAM-1 blocking antibodies prevented 
ROS production and cytoskeletal changes induced by neutrophil adhesion, 
indicating that ICAM is upstream of ROS production. The source of ROS was 
identified as xanthine oxidase. P38 mitogen-activated protein kinase (MAPK) was 
later shown to be a downstream target of ROS in this system [101]. These 
studies were performed in pulmonary microvascular endothelial cells. 
Interestingly, similar experiments in pulmonary arterial cells did not yield similar 
results [102], indicating that there may be potential differences in signaling 
pathways between cells from microvasculature versus large vessel cells. 
Differences in cell culture models may also explain the findings of Martinelli et al. 
Using antibody crosslinking, they found that activation of ICAM-1 in immortalized 
rat brain endothelial cells stimulated nitric oxide synthase (eNOS), and not 
NADPH oxidase [103].  
By activating Rac1, VCAM-1 crosslinking results in NADPH oxidase 
activation and ROS production in ECs [104].  Generation of low levels of ROS 
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upon VCAM-1 engagement is required for stereotypical actin cytoskeleton 
changes to occur.  Extracellular release of ROS due to VCAM signaling results in 
the activation of EC-associated matrix metalloproteases (MMPs) [105], and this 
ROS-mediated activation of MMPs was required for efficient lymphocyte 
migration.  This could potentially regulate TEM by MMP-mediated degradation of 
junctional components such as VE-cadherin.  Evidence has been presented that 
ROS activates the redox-sensitive kinase Pyk2 [50].  Pyk2 phosphorylates β-
catenin promoting its dissociation from VE-cadherin.  Another kinase, PKC-α, 
was shown to be activated by oxidation downstream of VCAM.  This activation 
was DAG-independent, and was required for efficient TEM of splenic 
lymphocytes [106].  Subsequently, the downstream target of PKC-α in this 
pathway was discovered to be protein tyrosine phosphatase 1B (PTP1B) [107].  
The exact mechanism of how PTP1B activity promotes lymphocyte TEM remains 
to be determined; however this is yet another indication that a balance of 
phosphorylation is important for the maintenance of junctional integrity and that 
ROS may play a role in determining this balance.  
 Phagocytic cells generate high concentrations of extracellular ROS in a 
respiratory burst event mediated by the NADPH oxidase complex [108].  
Exogenous ROS have been shown to enhance neutrophil binding to ECs due to 
increased expression of EC cell surface adhesion molecules [109].  Additionally, 
ROS released from fMLP-stimulated neutrophils was found to increase vascular 
permeability [110].  It is intriguing to consider that leukocyte-generated ROS may 
act locally on ECs to trigger intracellular signaling that facilitates TEM.  This 
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mechanism of signaling may amplify existing signals initiated by EC-generated 
ROS or initiate separate pathways. One potential pathway for amplification of 
existing signals by ROS is stimulation of adhesion molecule expression. In vitro 
experiments have shown that treatment of endothelial cells with ROS, increases 
neutrophil adhesion due to enhanced ICAM-1 expression [111]. Similar results 
were obtained in vivo, in which animals were infused with hypoxanthine and 
xanthine oxidase as a superoxide generating system [112]. Intravital microscopy 
of mesenteric vessels showed that ROS promoted leukocyte adhesion and that 
this effect could be overcome by administration of antibodies against ICAM-1 
integrin ligands.  
Tyrosine phosphorylation of junctional proteins 
 VE-cadherin plays a critical role in regulating paracellular permeability 
during TEM.  Adhesion of leukocytes to ECs has been shown to induce a 
localized, transient disruption of VE-cadherin which is required for efficient TEM 
[113]. Tyrosine phosphorylation of junctional components has been implicated as 
an important mechanism for regulating junctional integrity during TEM.  For 
example, inhibition of protein tyrosine phosphatases in ECs increases tyrosine 
phosphorylation of AJ components and promotes neutrophil TEM [28, 114].   
ICAM-1 engagement results in tyrosine phosphorylation of VE-cadherin through 
activation of Src and Pyk2 kinases [115].  Phosphorylation on tyrosines 658 and 
731 inhibits binding of p120-catenin and β-catenin [30], and increases TEM of 
neutrophils [115].  Similarly, ICAM-mediated VE-cadherin phosphorylation in 
brain microvascular cells increased paracellular TEM of lymphocytes [116].  
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Interestingly, this pathway involving ICAM-1 activation leading to VE-cadherin 
phosphorylation has also been shown to require nitric oxide signaling [103]. This 
is yet another example of the important role of ROS/RNS in TEM.  
Src activation due to ICAM signaling has been reported previously to 
induce tyrosine phosphorylation of a number of proteins including cortactin [117].  
A pathway has been defined linking cortactin phosphorylation to TEM of 
neutrophils [118].  It was concluded that cortactin phosphorylation by Src serves 
to link ICAM-1 to the actin cytoskeleton, aiding ICAM-1 clustering at sites of 
leukocyte adhesion. 
Chapter 2: Direct activation of RhoA by reactive oxygen species requires a 
redox-sensitive motif 
 
Summary 
Rho family GTPases are critical regulators of the cytoskeleton and affect 
cell migration, cell-cell adhesion, and cell-matrix adhesion. As with all GTPases, 
their activity is determined by their guanine nucleotide-bound state. 
Understanding how Rho proteins are activated and inactivated has largely 
focused on regulatory proteins such as guanine nucleotide exchange factors 
(GEFs) and GTPase activating proteins (GAPs). However, recent in vitro studies 
have indicated that GTPases may also be directly regulated by redox agents. We 
hypothesized that this redox-based mechanism occurs in cells and affects 
cytoskeletal dynamics, and in this report we conclude this is indeed a novel 
mechanism of regulating the GTPase RhoA. We show that RhoA can be directly 
activated by reactive oxygen species (ROS) in cells, and that this requires two 
critical cysteine residues located in a unique redox-sensitive motif within the 
phosphoryl binding loop. 
First, we show that ROS can reversibly activate RhoA and induce stress 
fiber formation, a well characterized readout of RhoA activity. To determine the 
role of cysteine residues in this mechanism of regulation, we generated cysteine 
to alanine RhoA mutants. Mutation of these cysteines abolishes ROS-mediated 
activation and stress fiber formation, indicating that these residues are critical for 
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redox-regulation of RhoA. Importantly, these mutants maintain the ability to be 
activated by GEFs . Our findings identify a novel mechanism for the regulation of 
RhoA in cells by ROS, which is independent of classical regulatory proteins. This 
mechanism of regulation may be particularly relevant in pathological conditions 
where ROS are generated and the cellular redox-balance altered, such as in 
asthma and ischemia-reperfusion injury. 
Introduction 
Rho family GTPases serve as critical regulators of cell migration, cell-cell 
adhesion, and cell-matrix adhesion, by transmitting extracellular and intracellular 
signals to effectors that act on the cytoskeleton.  The best characterized 
members of the Rho family of GTPases are RhoA, Rac1, and Cdc42; each of 
which is associated with unique phenotypes and functions [119-121]. As with all 
canonical GTPases, the activity of Rho GTPases is determined by their guanine 
nucleotide-bound state.  Rho GTPases are activated by binding GTP, which 
causes a conformational change in the protein that greatly increases the affinity 
for downstream effector proteins.  These effector proteins are components of 
signaling cascades which ultimately lead to modulation of cellular functions.  
Conversely, GDP-bound Rho GTPases are unable to bind effector proteins and 
are therefore inactive.  The switching between “on” and “off” states is tightly 
controlled by regulatory proteins which interact with GTPases to regulate guanine 
nucleotide binding [33]. Guanine nucleotide exchange factors (GEFs) activate 
GTPases by promoting the dissociation of GDP to allow the binding of GTP, 
which is available in great excess over GDP levels in the cytoplasm.  GTPase 
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activating proteins (GAPs) promote the hydrolysis of GTP to GDP, preventing 
GTPase interaction with downstream effectors.  GDP-dissociation inhibitors 
(GDIs) maintain the inactive state of the GTPase by preventing GDP-dissociation 
and membrane association [122].  All of these regulatory proteins are themselves 
affected by diverse upstream signals which serve to activate or inactivate Rho 
GTPase signaling pathways. 
Yet another mechanism for regulating GTPase activity has been proposed 
that involves the action of redox agents, specifically reactive oxygen species 
(ROS) and reactive nitrogen species (RNS).  ROS and RNS have been 
historically considered pathological agents which can react with and damage 
many biological macromolecules including DNA, proteins and lipids. However, 
there has been an increasing recognition that ROS and RNS can also function in 
cell signaling pathways [123, 124] in particular, those pathways involving 
phosphatases [125].  Most cell types produce ROS, either as byproducts of 
normal metabolism or by specific enzyme complexes.  A major source of ROS in 
cells is the NADPH oxidase complex, which can be activated by Rac1 [126-128].  
This generation of ROS by Rac1 has been implicated in the redox-mediated 
regulation of RhoA activity. Nimnual et al. described a novel mechanism in which 
downregulation of RhoA occurs via redox-mediated inactivation of the 
phosphatase LMW-PTP and subsequent elevation of p190 RhoGAP activity [57].  
As well as affecting regulatory protein function, another body of work 
shows that at least in vitro, oxidizing agents can also directly regulate the activity 
of certain GTPases. Lander et al. were the first to show this with Ras; NO 
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treatment of recombinant Ras increased the proportion of GTP-bound Ras and 
endogenous NO activated Ras in human T cells [61, 129].  Campbell’s group 
went on to describe a radical-based mechanism for the stimulation of nucleotide 
exchange on Ras by NO [130].  Interestingly, Campbell’s group also identified a 
distinct redox-active motif located in the phosphoryl-binding loop in another 
subset of GTPases, the Rho family (RhoA, Rac1, and Cdc42) [63].  They found 
that treatment of purified recombinant GTPase with superoxide anion radical or 
nitrogen dioxide radicals in vitro resulted in guanine nucleotide dissociation.  The 
proposed mechanism involves electron transfer of a thiol radical intermediate to 
the guanine base, which disrupts interactions between the guanine nucleotide 
and the GTPase, resulting in guanine nucleotide dissociation.  In the presence of 
radical quenching agents, the intermediates are reversed and guanine nucleotide 
association can occur.  Under conditions where GTP is in excess, such as in the 
cell, the end result is exchange of GDP for GTP, thereby activating the GTPase.  
Based on these in vitro findings, we hypothesize that ROS can directly affect 
GTPase activity in cells by oxidative modification of the critical cysteine residues 
within the redox-active motif.  This may be a novel mechanism of regulating 
GTPase signaling cascades, independent but parallel to classical regulation by 
GEFs and GAPs. 
In this paper, we show that RhoA can be directly activated by ROS in cells 
and that ROS-mediated activation of RhoA can induce cytoskeletal 
rearrangement.  By using cysteine to alanine mutants, we demonstrate that 
ROS-mediated activation of RhoA is dependent on cysteines 16 and 20.  Our 
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findings indicate that ROS-mediated RhoA activation is another potential 
regulatory mechanism in cells that can affect cytoskeletal dynamics.  
Results 
ROS induces reversible activation of RhoA  
Peroxides are short-lived, membrane permeable oxidants that are 
generated in vivo by enzymatic complexes and as byproducts of cellular 
metabolism.  To determine if exogenous ROS affects the activity of cellular 
RhoA, we treated REF-52 fibroblasts with low doses (0.1 µM to 10 µM) of a 
stable analog of hydrogen peroxide, t-butyl hydroperoxide (peroxide), for 10 min 
under serum-free conditions.  The doses of exogenous peroxide used are 
physiologically relevant, based on measurements of intracellular ROS production 
made by others [123, 131].  Using standard Rhotekin-RBD pulldown assays, we 
observed that RhoA was significantly activated by peroxide treatment, as shown 
in Figure 4A and the accompanying quantification.  To determine whether this 
activation is reversible, we treated REF-52 fibroblasts with 0.1 µM peroxide for 10 
min, followed by washout with media only (Figure 4B).  0.1 µM peroxide activates 
endogenous RhoA, but the activity returns to baseline levels within 15-30 min 
upon washout.  This reversibility suggests that the reducing environment of the 
cytoplasm and presence of intracellular anti-oxidants rapidly quench the effects 
of a bolus dose of exogenous peroxide.  To determine whether endogenous ROS 
can activate RhoA, we used antimycin A, a compound that inhibits electron 
transport at complex III of the mitrochondrial respiratory chain, thereby inducing 
the production of superoxide and other ROS [132, 133] (Figure 4C).  Treatment 
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of cells with antimycin A resulted in activation of RhoA (Figure 4D).  This 
activation was prevented by the presence of N-acetyl cysteine (NAC), a free 
radical and ROS scavenger.  Having confirmed that endogenous ROS exerts the 
same effect on RhoA as extracellular peroxide, for all remaining experiments we 
use peroxide instead of antimycin A.  We also examined whether peroxide would 
activate Rac1 in cells. With REF-52 fibroblasts, low levels of activation were 
detected in some experiments, but this was variable.  However, with both HeLa 
cells (Figure 9) and endothelial cells (data not shown), we routinely observe 
robust activation of Rac1 in response to exogenous peroxide at 0.1 µM to 10 µM 
concentrations. 
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Figure 4. RhoA is reversibly activated upon exposure to ROS. (A) REF-52 fibroblasts were 
serum-starved followed by treatment with the indicated concentrations of t-butyl hydroperoxide 
(peroxide) in serum-free DMEM for 10 min.  RhoA activity assays show that peroxide treatment 
results in the activation of endogenous RhoA.  A representative blot of active RhoA sedimented 
by GST-RBD versus total RhoA from whole cell lysates is shown.  ImageJ software was used to 
quantify RhoA activation. Relative RhoA activity is the ratio of active RhoA divided by total RhoA 
normalized to the untreated control.  Graph represents the average +/- SEM of 5 independent 
experiments. * p<0.05 (B) REF-52 fibroblasts were serum-starved and treated as above with 100 
nM peroxide for 10 min.  Following peroxide treatment, the medium was either left unchanged (0’) 
or replaced with serum-free DMEM for 15 or 30 min (15’, 30’).  The RhoA activity assay shows 
that peroxide-induced RhoA activation is reversible after washout. (C) Antimycin A induces ROS 
production. REF52 fibroblasts were loaded with 5 µM dichlorofluorescin diacetate (DCFDA) for 30 
min under serum free conditions, followed by stimulation with 10 µM antimycin A (AA) for 5, 15 or 
30 min. Stimulation with 10 µM peroxide for 5 min was used as a positive control. (D) REF-52 
fibroblasts were serum-starved with or without 0.5 µM NAC followed by treatment with 10 µM 
antimycin A (AA) for 30 min.  RhoA activity assays show that treatment with antimycin A results in 
the activation of endogenous RhoA.  However, this activation is inhibited in cells pre-treated with 
NAC.  Representative blots of active RhoA sedimented by GST-RBD versus total RhoA from 
whole cell lysates are shown.  ImageJ software was used to quantify RhoA activation.  Relative 
RhoA activity is the ratio of active RhoA divided by total RhoA normalized to the untreated 
control.  Graph represents the average +/- SD of 3 independent experiments. * p<0.05, not 
signficiant (NS) 
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ROS treatment induces stress fiber formation. 
To further explore what functional consequences this ROS-mediated 
RhoA activation might have in a cellular context, we looked at stress fiber 
formation as it is a well-characterized cellular readout of Rho activity [120].  For 
these experiments, Rat2 cells were used because upon serum-starvation they 
readily lose stress fibers, allowing a low baseline from which induction of stress 
fibers could be induced and more readily quantified. Rat2 cells were serum-
starved for 1 h to cause loss of stress fibers, and then treated with either 5% FBS 
as a positive control, or 1 µM peroxide for 15 min.  Cells were fixed and F-actin 
was detected with Texas-Red labeled phalloidin.  As expected, serum starvation 
results in significant loss of actin stress fibers in Rat2 fibroblasts (Figure 5A).  
Importantly, peroxide treatment induced formation of prominent stress fibers to a 
similar extent as adding back serum (Figure 5A).  Stress fiber induction was 
quantified by scoring cells for the presence of stress fibers and is represented as 
an index of stress fiber induction in Figure 5B.  The induction of stress fibers by 
peroxide and FBS correlated with activation of RhoA in Rat2 cells (Figure 5C).  
To further show the role of RhoA in the induction of stress fibers by peroxide and 
FBS, we used the Rho kinase inhibitor Y27632. Y27632 inhibits Rho kinase and 
therefore Rho-mediated contractility, preventing the formation of stress fibers 
[132].  Pre-treatment with Y27632 significantly reduced the percent of cells with 
prominent stress fibers after peroxide or FBS treatment (Figure 5D).  The ability 
of ROS to induce cytoskeletal alterations has been described previously, 
particularly in the context of oxidant-mediated changes in endothelial cell 
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permeability. These studies used both exogenous hydrogen peroxide [133-135], 
or superoxide and related molecules produced via the xanthine oxidase system 
[136].  It is important to note that these studies used peroxide concentrations in 
the range of 100-250 µM, and/or treatment for much longer time (1-6 hours) than 
we have utilized here (1 µM for 15 min).  In addition to the formation of stress 
fibers, ROS treatment caused monolayer gap formation and increased 
permeability in these studies [134, 136], which is also indicative of elevated RhoA 
activity and increased actomyosin contractility induced via the Rho/Rho kinase 
signaling pathway.  Consistent with these earlier reports, the data in Figure 4 and 
Figure 5 reveal that low concentrations of ROS activate RhoA and promote 
stress fiber formation in fibroblasts. 
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Figure 5. ROS treatment induces stress fiber formation. (A) Rat2 fibroblasts were grown on 
fibronectin-coated coverslips and either untreated, serum-starved for 1 h, or serum-starved 
followed by 15 min treatment with 5% FBS or 1 µM peroxide.  F-actin staining was detected with 
Texas-Red labeled phalloidin.  Serum-starvation results in loss of actin stress fibers; treatment 
with either FBS or peroxide induces prominent stress fibers.  (B) Cells treated as above were 
scored for the presence of stress fibers and graphed as an index of stress fiber induction 
(normalized to serum-starved).  Both FBS and peroxide result in an equally significant induction 
of stress fibers.  Graph represents the mean of 3 independent experiments ± SD, with > 300 cells 
counted for each condition.  Actual percent cells with stress fibers for each condition is 75.3 ± 
7.5% (untreated), 42.3 ± 4.6% (starved), 64.3 ± 6.1% (serum-starved and peroxide treated), and 
73 ± 6.4% (serum-starved and FBS treated). * p < 0.05 (C) Rat2 fibroblasts were serum-starved 
for 1 hr, followed by treatment with either 1 µM peroxide or 5% FBS for 15 min.  RhoA activity 
assays show that both peroxide and FBS activate RhoA.  A representative blot of active RhoA 
sedimented by GST-RBD versus total RhoA from whole cell lysates is shown.  ImageJ software 
was used to quantify RhoA activation.  Relative RhoA activity is the ratio of active RhoA divided 
by total RhoA normalized to the untreated control.  Graph represents the average +/- SD of 2 
independent experiments. * p<0.05 (D) Rat2 cells were grown as in panel A, serum-starved for 1 
hr  ± 5 µM Y27632, and then treated for 15 min with 1 µM peroxide or 5% FBS.  F-actin staining 
was detected with Texas-Red labeled phalloidin.  Pre-treatment with Y27632 significantly reduces 
the percent of cells with prominent stress fibers after both peroxide and FBS treatment.  Graph 
represents the mean of 3 independent experiments ± SD with >300 cells counted for each 
condition. 
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Redox-sensitive cysteine residues are required for ROS-mediated activation of RhoA  
What is the mechanism for this redox regulation of RhoA?  Previously 
published in vitro observations have shown that RhoA has a redox-sensitive motif 
(GXXXCGK(S/T)C) containing two cysteine residues in the phosphoryl binding 
loop [63, 64].  As shown in Figure 6A, these cysteine residues are conserved in 
human, mouse, and rat RhoA. Previous in vitro studies revealed that oxidation of 
these cysteine residues, particularly cysteine 20, resulted in displacement of the 
bound nucleotide.  Subsequent reduction allowed nucleotide to rebind, i.e. for 
nucleotide exchange to occur [63, 64].  To test whether these residues might play 
a role in the regulation of RhoA activity in cells by ROS, we mutated both 
cysteine 16 and 20 to alanine residues, thus making them resistant to oxidative 
modification.  To prevent interference of endogenous RhoA in our experiments, 
we designed an adenovirally delivered miRNA construct targeted against a 
conserved region of RhoA, as shown in Figure 6B.  Myc-tagged, non-targeted 
wildtype (wt) and CA (C16/20A) mutants were designed with 5 silent mutations 
within the miRNA targeting sequence, thus allowing re-expression of the myc-
tagged wt and C16/20A mutant proteins.  Figure 6C demonstrates effective 
knockdown of endogenous RhoA and simultaneous re-expression of either wt or 
C16/20A myc-RhoA.  Importantly, these myc-tagged, non-targeted RhoA 
constructs retain the ability to bind GTP as shown by GST-RBD pulldown assays 
in Figure 6D. 
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Figure 6: Characterization of RhoA miRNA and re-expression of non-targetable (NT) redox-
resistant RhoA mutant constructs.  (A) RhoA protein sequence (amino acids 1-25) showing 
conserved putative redox-sensitive cysteines C16 and C20 (shaded residues). (B) Nucleotide 
sequence (bp 43-87) of rat, mouse, and human RhoA showing the region targeted by the RhoA 
miRNA used in this study (shaded area).  To re-express non-targeted RhoA constructs five silent 
mutations were introduced in the miRNA targeting region (black boxes).  Nucleotides 
corresponding to C16 and C20 are underlined. (C) Knockdown of endogenous RhoA and 
simultaneous re-expression of non-targeted (NT) mutant constructs.  REF-52 cells were infected 
with negative control or RhoA miRNA-encoding adenovirus together with virus encoding wt or 
C16/20A myc-RhoA where indicated. After 72 hours, total cell lysates were analyzed by western 
blot with a RhoA and B-actin antibody (loading control).  Arrowhead indicates endogenous RhoA; 
arrow indicates the slower migrating non-targeting, myc-RhoA constructs. (D) Activity assay of wt 
and C16/20A myc-RhoA constructs.  REF-52 cells were infected with negative control or RhoA 
miRNA-encoding adenovirus together with virus encoding wt or C16/20A myc-RhoA.  After 72 
hours, cells were processed for RhoA activity assays (in the presence of serum) and analyzed by 
western blot with a myc antibody.  
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To test whether cysteine 16 and 20 are required for the redox-sensitivity of 
RhoA, we examined the ability of C16/20A myc-RhoA to be activated by ROS in 
cells.  REF52 cells expressing wt or C16/20A myc-RhoA were treated with 
various doses of peroxide under serum-free conditions, followed by RBD 
pulldown assay to detect RhoA activity.  As shown in Figure 7A and the 
accompanying quantification (Figure 7B), while wt myc-RhoA responds to 
peroxide similarly to endogenous RhoA with activation over baseline levels, the 
C16/20A myc-RhoA mutant is resistant to activation by ROS.  Importantly, data 
shown in Figure 7 indicate that while the C16/20A RhoA mutant is unresponsive 
to ROS treatment, it is still capable of being activated and inactivated by other 
physiological stimuli.  Thrombin treatment is a well-characterized stimulus that 
induces RhoA activation in a wide variety of cell types [137, 138], an effect that is 
mediated through the action of p115 RhoGEF, among others [139-141].  Figure 
7C shows that thrombin treatment activates wt RhoA as expected, and also 
rapidly activates C16/20A myc-RhoA, indicating that the mutant retains the ability 
to be activated by GEFs.  Conversely, we tested the ability of C3 toxin to 
inactivate C16/20A myc-RhoA.  C3 inactivates RhoA by ADP-ribosylation, and 
treatment of cells with this toxin results in a characteristic dendritic phenotype 
[142, 143].  REF52 cells expressing either wt or C16/20A myc-RhoA  respond to 
C3 as indicated by this altered morphology (Figure 7D).  Together, the results 
shown in Figure 7 indicate that the cysteine to alanine mutations confer 
resistance to ROS-mediated GTPase activation, but notably, still maintain 
responsiveness of the GTPase to other physiological stimuli. 
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Figure 7. C16/20A myc-RhoA is not activated by ROS but responds normally to other 
physiological stimuli. (A) REF-52 cells expressing wt or C16/20A myc-RhoA were serum-
starved and treated with the indicated concentrations of peroxide for 10 min.  RhoA activity 
assays show that the activity of wt myc-RhoA increases in response to peroxide, however, the 
C16/20A mutant is resistant to activation by peroxide.  (B) ImageJ software was used to quantify 
RhoA activation.  Peroxide treated conditions are normalized to the corresponding untreated 
controls.  Graph represents the average +/- SEM of 2 independent experiments. * p<0.05 
compared to untreated control. (C) REF-52 cells in which endogenous RhoA had been knocked 
down and re-expressing wt or C16/20A myc-RhoA were serum starved and treated with 1 U/mL 
thrombin to test their responsiveness to GEF-mediated activation.  RhoA activity assays show 
that both wt and C16/20A myc-RhoA are activated by thrombin at 1 and 5 min. (D) REF-52 cells 
in which endogenous RhoA had been knocked down and expressing wt or C16/20A myc-RhoA 
were treated with either GST alone or GST-C3, as described in the methods.  F-actin staining 
was detected with Texas-Red labeled phalloidin.  C3 treatment results in a characteristic dendritic 
morphology due to RhoA inactivation.  Cells expressing either wt or C16/20A myc-RhoA develop 
the C3 phenotype.  
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ROS-mediated stress fiber induction requires redox-regulation of RhoA. 
We went on to test how the CA mutations affect the cellular function of 
RhoA by measuring peroxide-induced stress fiber induction in Rat2 cells as in 
Figure 8, but with cells re-expressing either wt or C16/20A myc-RhoA after 
knockdown of the endogenous protein.  As shown in Figure 8, both wt and 
C16/20A myc-RhoA expressing cells have an equivalent amount of stress fibers 
in an unstarved state, and both lose stress fibers to a similar degree upon serum-
starvation. However, while addition of 1 µM peroxide for 15 min induces stress 
fiber formation in cells re-expressing wt myc-RhoA cells expressing C16/20A 
myc-RhoA do not show any significant induction of stress fibers.  These results 
confirm that cysteine 16 and/or 20 are specifically required for ROS-induced 
stress fiber formation by RhoA. 
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Figure 8. ROS induction of stress fibers is dependent on redox-regulation of RhoA. Rat2 
fibroblasts were infected with adenoviruses to knockdown endogenous RhoA and re-express wt 
or C16/20A myc-RhoA.  These cells were seeded on fibronectin-coated coverslips, and either left 
unstarved (DMEM + 5% FBS), or serum-starved for 1 h followed by treatment with DMEM alone, 
or 1 µM peroxide in DMEM for 15 min.  Quantitation of stress fiber induction shows that 
compared with the starved condition, peroxide treatment induces a statistically significant 
increase in stress fibers in cells expressing wt myc-RhoA but not in cells expressing redox-
resistant C16/20A myc-RhoA.  Graph represents the mean of 3 independent experiments, with > 
300 cells counted for each condition (error bars equal SD). * p<0.05; NS, not significant.  Actual 
percent cells with stress fibers for each condition is: (unstarved) wt myc-RhoA 76.7 ± 5.0%, 
C16/20A myc-RhoA 78.1 ± 5.2%; (starved) wt myc-RhoA 48.3 ± 5.7%, C16/20A myc-RhoA 49.6 
± 5.0%; (peroxide) wt myc-RhoA 68.5 ± 4.9%, C16/20A myc-RhoA 46.3 ± 7.4%.  
 44 
 
 
Figure 9. Rac1 activation by peroxide. Peroxide activates Rac1 in Hela cells. HeLa cells were 
serum-starved and treated with the indicated concentrations of peroxide for 10 min. Rac1 activity 
assays show that peroxide treatment results in activation of endogenous Rac1. A representative 
blot of active Rac1 sedimented by GST-PBD versus total Rac1 from whole cell lysates is shown. 
ImageJ software was used to quantify Rac1 activation. Graph represents the average +/- SD of 2 
independent experiments. * p < .05 versus untreated control.  
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Discussion 
ROS and RNS have been implicated in a variety of cell signaling 
pathways, including growth factor signaling [123, 124], inflammation [144], 
engagement of integrins [145, 146], and adhesion to extracellular matrix 
(reviewed in [147]).  Hydrogen peroxide in particular has gained considerable 
attention as a potent signaling molecule [47].  Hydrogen peroxide and other ROS 
have been shown to be generated both intracellularly and extracellularly.  
Extracellular ROS generated by neutrophils can act on endothelial cells to affect 
vascular permeability [110] and EGF receptor engagement has been shown to 
induce the production of extracellular peroxide which can then permeate the cell 
membrane to affect intracellular signaling [148, 149].  Most recently, the role of 
paracrine signaling by externally-produced peroxide has been shown in a 
zebrafish wound healing model.  Niethammer et al. show that injured epithelial 
cells secrete peroxide (in the range of 0.5 to 50 uM) to induce leukocyte 
recruitment to the wound [150]. 
There is strong evidence that Rac1-derived ROS can lead to oxidative 
inactivation of LMW-PTP, resulting in phosphorylation and activation of 
p190RhoGAP and subsequent downregulation of RhoA [57].  However, several 
studies have demonstrated that exogenous peroxide induces effects consistent 
with activation of RhoA [133-135, 151].  Furthermore, Campbell et al. 
demonstrated in vitro that ROS and RNS induce nucleotide displacement by 
direct cysteine oxidation in the phosphoryl-binding site of RhoA.  If this oxidative 
event is reversed by reduction and GTP is present in excess, nucleotide 
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exchange (GTP binding) is favored and the GTPase is activated [64].  Notably, 
this occurs in the absence of GEFs.  Our data support the mechanism described 
from their in vitro observations.  We show that the activation of RhoA by peroxide 
is prevented by cysteine to alanine mutation of residues 16 and 20, although this 
mutant RhoA behaves normally in response to GEF-mediated situations 
(thrombin stimulation).  
It is interesting that Zuckerbraun et al. found that treatment of cells with 
NO inhibits RhoA activity [152].  This apparent discrepancy has been observed in 
cell-based studies of the Ras GTPase, where both activation and inactivation of 
Ras have been observed in the presence of exogenously supplied RNS [153].  
Redox regulation of Ras and Rho GTPase activity is likely to be dependent on a 
number of factors, including the type and level of cellular oxidants, reduction 
potential, as well as differences in cell lines resulting from variations in redox 
enzymes.  If the oxidizing agent is in excess, or in the absence of a cellular 
reducing agent such as GSH, loss of GDP from RhoA can result in intramolecular 
disulfide formation between C16 and C20, and this form of RhoA is inactive, as it 
cannot bind nucleotide or interact with the GEF, Vav2, in in vitro studies [64].  
However, under conditions where ROS/RNS are present at physiological levels 
and the reduction potential is high, as is the case within the cell cytoplasm, 
GTPase activation is expected, which is what we observe under our experimental 
conditions.   
The cell’s redox environment may also play a role in distinguishing 
regulation of RhoA by ROS as opposed to classical regulation by GEFs and 
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GAPs.  It is likely that ROS-mediated pathways are occurring parallel to 
pathways involving classical regulatory proteins.  However, since ROS are 
typically very reactive and have short half-lives, direct regulation of RhoA by ROS 
is likely to be more spatially and temporally confined.  This confinement may be 
relaxed under conditions where the cell’s redox environment is out of balance.  
Certainly, there are situations where ROS are generated at increased levels 
physiologically and pathologically.  For example, the respiratory system is 
normally exposed to greater concentrations of ROS than other tissues.  
Pulmonary diseases associated with airway hyperresponsiveness, such as 
asthma and COPD, have been shown to be associated with increased ROS 
production [154].  ROS and RhoA activation have been attributed to tracheal 
smooth muscle contractility, which is a hallmark of these disease states [155, 
156].  We suspect that increased levels of ROS under these conditions may 
directly activate RhoA to drive smooth muscle contractility.  Similarly, ischemia-
reperfusion injury is associated with increased ROS production, which leads to 
pathology of the vascular system [157].  ROS-mediated activation of RhoA has 
been demonstrated in vascular smooth muscle [158].  Based on our results, we 
would predict that ROS may activate RhoA signaling in smooth muscle and in the 
endothelium, contributing to the massive increases in vascular permeability 
associated with ischemia-reperfusion injury. 
In addition, we suspect that other Rho family GTPases may be directly 
regulated by ROS given the work of Campbell et al. [63] .  For example, we show 
that Rac1 activity is regulated by peroxide in epithelial and endothelial cells 
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(Figure 9 and data not shown).  The regulation of Rac1 by ROS is particularly 
interesting because of its involvement in ROS production, through the NADPH 
oxidase complex [128], and its regulation by superoxide dismutase-1 (SOD1) 
[159]. SOD1 modulates intracellular ROS by converting superoxide to hydrogen 
peroxide.  This creates a potential feedback loop in which Rac1 activity 
generates ROS which can regulate Rac1 activity through the redox-dependent 
sensor SOD1.  Overall, these effects may be cell type specific, as the localization 
of a particular GTPase and baseline levels of activity likely play an important role 
in how that GTPase responds to ROS in terms of activity and phenotypic 
response. 
We have shown that ROS can regulate RhoA activity in cells via a 
mechanism involving critical cysteine residues present in a redox-sensitive motif. 
This ROS-based mechanism of regulation was previously suggested by 
biochemical studies in vitro [64].  Our data support this occurring within cells and 
furthermore show that in a cellular context oxidative modification of these 
residues is a novel mechanism that can affect cytoskeletal dynamics.  
Materials and Methods 
Chemicals 
T-butyl peroxide (peroxide) and N-acetyl cysteine (NAC) were purchased from 
Sigma-Aldrich (St. Louis, MO). Antimycin A was purchased from Axxora (San 
Diego, CA).  Y-27632 was purchased from Calbiochem/EMD Chemicals 
(Gibbstown, NJ). 6-carboxy-2′,7′-dichlorodihydrofluorescein diacetate 
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di(acetoxymethyl ester) (DCFDA) was purchased from Molecular Probes 
(Eugene, OR). 
Cell Lines 
REF52 [160], Rat2 fibroblasts (CRL-1764, American Type Culture Collection), 
and HeLa cells (CCL-2, American Type Culture Collection) were grown in 
Dulbecco’s modified Eagle’s medium (DMEM; Gibco) supplemented with 10% 
fetal bovine serum (FBS; Sigma) and antibiotic-antimycotic solution (Gibco).  
Knockdown of RhoA using miRNA adenovirus 
miRNA adenoviral constructs were designed and engineered using the BLOCK-
iT TM Pol II miR RNAi expression vector system (Invitrogen) according to the 
manufacturer’s protocol (Invitrogen).  Briefly, double-stranded oligonucleotides 
were designed using Invitrogen’s RNAi Designer (www.invitrogen.com/rnai) to 
form an engineered pre-miRNA sequence structure that targets a conserved 
region in human, mouse, and rat RhoA:  
5’TGCTGAAGACTATGAGCAAGCATGTCGTTTTGGCCACTGACTGACGACAT
GCTCTCATAGTCTT3’ (21 bp antisense target sequence underlined).   
Synthesized oligonucleotides were annealed and ligated into pcDNA 6.2-GW/ 
EmGFP-miR.  The EmGFP-miRNA cassette was subsequently shuttled through 
pDONR221(Invitrogen) by Gateway BP recombination and then into pAd-CMV-
Dest Gateway vector by LR recombination.  Each construct was sequence 
verified and virus was produced in 293A packaging cell line with the ViraPower 
Adenoviral Expression System (Invitrogen) using the manufacturer’s 
recommended protocol. 
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Generation of non-targeting RhoA constructs and adenoviral-mediated expression 
In order to simultaneously knockdown endogenous RhoA while allowing re-
expression of RhoA mutants, non-targeting RhoA constructs were designed.  
Human RhoA in pCMV-myc was used as a template for site-directed 
mutagenesis (QuikChange II Site-Directed Mutagenesis kit; Stratagene), wherein 
5 silent DNA basepair mutations were made within the miRNA targeting region of 
RhoA.  This non-targeted form of RhoA was then used as a template for site-
directed mutagenesis in order to generate cysteine to alanine mutants at C16 
and C20 (C16/20A myc-RhoA).  Adenovirus was generated using the Virapower 
adenoviral expression system (Invitrogen) following the manufacturer’s protocol 
as described above.  For experiments, cells were infected by overnight 
incubation with adenovirus-containing media followed by addition of fresh 
DMEM/10% FBS for another 48 h.  
Immunohistochemistry and measurement of stress fiber induction 
Rat2 cells treated with adenovirus to knockdown endogenous RhoA while re-
expressing either wt myc-RhoA or C16/20A  myc-RhoA were plated onto 
fibronectin-coated coverslips (15 ug/ml) overnight, followed by serum-starvation 
for 1 h.  Cells were treated for 15 min with either serum-free or 1 µM peroxide-
containing DMEM, or 5% FBS-containing DMEM (positive control) before 
fixing/permeabilizing in 3.7% paraformaldehyde, then 0.02% Triton X-100.  In 
some experiments, Rat2 cells were starved in the presence of 5 µM Y27632.  
Texas Red phalloidin (Molecular Probes) was used to stain F-actin.  
Immunofluorescence images were taken through a 20x objective (Zeiss plan-
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Apochromat 20x/0.8) with a Zeiss axiovert 200M microscope equipped with a 
Hamamatsu ORCA-ERAG digital camera and acquired using Metamorph 
Workstation (Universal Imaging Corp.).  To quantify stress fiber induction, GFP-
positive cells were scored by a blinded observer for the presence or absence of 
stress fibers; the criteria were: organized, thickened parallel actin bundles 
throughout the majority of the cytoplasm.  Results are plotted as a “stress fiber 
induction index” which was obtained by normalizing each treatment to the 
starved condition.  Statistical significance was determined by Student’s t-test of 
the average from 3 independent experiments. 
RhoA activity assays 
RhoA activity assays [161] were performed as described previously with minor 
modifications [162].  Cells were serum-starved in DMEM for 2 hours prior to 
performing assays to lower baseline RhoA activity and remove serum proteins 
which would interfere with experimental conditions.  Cells were washed with ice-
cold HEPES buffered saline (pH 7.4) and lysed in Buffer A (50 mM Tris pH 7.6, 
500 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholate, 10 mM MgCl2, 
100 µM orthovanadate and protease inhibitors).  Lysates were clarified by 
centrifugation and equalized for total volume and protein concentration. After 
incubation with glutathione S-transferase (GST)-Rho binding domain (RBD) 
beads, washing three times with ice-cold Buffer B (50 mM Tris pH 7.6, 150 mM 
NaCl, 1% Triton X-100, 0.5 mM MgCl2, 100 µM orthovanadate, with protease 
inhibitors, the bound fraction (active GTP-RhoA) was analyzed by SDS-PAGE.  
Total RhoA levels were similarly analyzed using a reserved aliquot of whole cell 
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lysate.  Active RhoA and total RhoA were analyzed by Western blotting with an 
anti-RhoA antibody (monoclonal antibody 26C4; Santa Cruz Biotechnology, 
Santa Cruz, CA).  The results were quantified using ImageJ software (NIH; 
Bethesda, MD).  The relative amount of active RhoA was determined by taking 
the ratio of RhoA sedimented by GST-RBD beads (active RhoA) divided by the 
amount of total RhoA in the whole cell lysate.  Statistical significance was 
determined using Student t-test (one-tailed).  
Rac1 activity assays 
Rac1 activity assays [58, 163] were performed as described previously with 
minor modifications [164]. Cells were serum-starved in DMEM for 1 hour prior to 
performing assays to lower baseline Rac1 activity and to remove serum proteins 
which would interfere with experimental treatments. Cells were washed with ice-
cold HEPES buffered saline (pH 7.4) and lysed in Buffer B (50 mM Tris pH 7.6, 
150 mM NaCl, 1% Triton X-100, 0.5 mM MgCl2, 100 µM orthovanadate, and 
protease inhibitors). Lysates were clarified by centrifugation and equalized for 
total volume and protein concentration. After incubation with glutathione S-
transferase (GST)-PAK binding domain (PBD) beads and washing three times 
with ice-cold Buffer B, the bound fraction (active GTP-Rac1) was analyzed by 
SDS-PAGE. Total Rac1 levels were similarly analyzed using a reserved aliquot 
of whole cell lysate. Active Rac1 and total Rac1 were analyzed by Western 
blotting with a monoclonal anti-Rac1 antibody clone 102 (BD Transduction 
Laboratories, San Jose, CA). The results were quantified using ImageJ software 
(NIH; Bethesda, MD). The relative amount of active Rac1 was determined by 
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taking the ratio of Rac1 sedimented by GST-PBD beads (active Rac1) divided by 
the amount of total Rac1 in the whole cell lysate. Statistical significance was 
determined using Student t-test (one-tailed). 
Measurement of ROS Generation 
Formation of ROS was monitored by the conversion of non-fluorescent 6-
carboxy-2′,7′-dichlorodihydrofluorescein diacetate di(acetoxymethyl ester) to 
fluorescent DCF. Cells were loaded with 5 µM DCF in serum-free DMEM for 30 
min at 37 °C. After loading, cells were washed twice with phosphate-buffered 
saline, and incubated for an additional 20 min at 37 °C to allow for dye de-
esterification. Cells were stimulated with antimycin A or peroxide as described in 
the figure legends. Fluorescence was determined using a fluorometer with an 
excitation of 485 and an emission of 520. 
C3 treatment 
GST-tagged recombinant proteins (either GST alone or GST-C3) were isolated 
from BL-21 bacteria using the manufacturer’s protocol for GST fusion proteins 
(Amersham Pharmacia Biotech).  Following adenovirus infection of REF-52 cells 
to knockdown endogenous and re-express wt or C16/20A myc-RhoA as 
described above, C3 toxin was introduced into these cells on coverslipsusing 
Lipofectamine according to the protocol of Maddox et al. [165].  After 3 hours of 
C3 exposure, cells were fixed and imaged as described above.
Chapter 3: Rho GTPases and ROS in regulating vascular permeability and 
TEM 
 
In this chapter, I will present and discuss a series of preliminary 
experiments in which I have examined the potential for GTPase regulation by 
ROS in endothelial cells. As discussed in Chapter 1, there is a significant body of 
work investigating Rho GTPases and ROS individually as critical regulators of 
endothelial cell-cell junctions and the processes which ultimately lead to 
leukocyte TEM. Many of these studies provide indirect evidence that Rho 
GTPases and ROS are connected, paving the way for my hypothesis that ROS 
can regulate Rho GTPase activity in endothelial cells and therefore impact 
permeability and TEM. 
ROS promote vascular permeability in vitro and in vivo 
Before specifically examining the role of ROS-mediated GTPase 
regulation, I will present preliminary evidence that ROS can regulate vascular 
permeability both in vitro and in vivo. This has been shown by others, but it was 
important for me to recapitulate the findings of others in my own experiments. 
Figure 10 shows the response of human umbilical vein endothelial cells 
(HUVECs) to low doses of exogenous hydrogen peroxide. 
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Measurement of transendothelial FITC-dextran flux shows increased 
permeability upon exposure to ROS over 30 minutes (figure 10A). 
Immunofluorescence studies by Erika Wittchen, shown in figure 10B, show 
disruption of VE-cadherin, a marker of EC junctions (arrowheads) after 15 
minutes of treatment with 100nM hydrogen peroxide. Together these results 
indicate that ROS significantly affect endothelial cells and reduce endothelial 
barrier function .  
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Figure 10. Peroxide treatment increases permeability of HUVEC monolayers. A. HUVECs 
were grown to confluence on matrigel coated transwell filters. Cells were treated with the 
indicated concentrations of hydrogen peroxide, and FITC-dextran was added to the upper 
chamber of the transwell. After 1 hr, media in the lower chamber was collected and fluorescence 
measured with a fluorometer. B. HUVECs were grown to confluence on matrigel coated glass 
coverslips. Cells were left either untreated or treated with 100nM hydrogen peroxide for 15 
minutes, and fixed with 3.7% formaldehyde solution. Coverslips were stained for the junctional 
marker VE-cadherin. As indicated by the arrowheads, peroxide treatment results in gaps in the 
endothelial junctions.  
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In collaboration with Tom Egan, a cardiothoracic surgeon here at UNC, we 
also examined the contribution of ROS to mediating vascular permeability in vivo 
using a mouse model of pulmonary ischemia reperfusion injury (IRI). IRI is a 
pathological consequence of restoring blood flow to ischemic tissues and results 
in damage to the endothelium and massive increases in vascular permeability. 
Much of the pathology associated with IRI has been attributed to ROS 
production, as will be discussed in chapter 4. To simulate pulmonary IRI, the 
hilum of the left lung of a mouse was clamped for 1 hour followed by reperfusion 
for 30 minutes. The left and right lungs were removed, and the wet mass to dry 
mass ratio of the tissue used as an indicator of tissue fluid retention. A larger 
wet/dry ratio is indicative of increased fluid retention and permeability. For each 
mouse, the right lung which was not clamped serves as an internal control.  
Figure 11 shows that IRI of the left lung significantly increased wet/dry ratio, 
without affecting the permeability of the sham control right lung. However, when 
mice were pretreated with the ROS scavenger N-acetylcysteine (NAC), wet/dry 
ratios for the IRI left lung remained unchanged from control levels. This indicates 
the significant contribution ROS makes to changes in vascular permeability in 
IRI, and potentially in inflammation in general. Similar results have been 
published by others [166]. Interestingly, RhoA activity is also increased in lungs 
which have undergone IRI surgery (Figure 11B). This corroborates our 
hypothesis that ROS generation, for example during IRI, can stimulate RhoA 
activation in vivo. 
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Figure 11. Scavenging ROS attenuates increased vascular permeability during IRI. A. Mice 
were subjected to IRI surgery as described in the text, and the lung tissue removed and weighed 
before and after drying. The wet/dry mass ratio serves as an indicator of edema and vascular 
permeability. IRI surgery on the left lung results in a significant increase in wet/dry ratio, whereas 
the sham control right lung is unaffected. *p < .05. Pre-treatment of the animals with the ROS 
scavenger N-acetylcysteine (NAC) prevents the increase in vascular permeability. Animals pre-
treated with saline serve as controls. B. Mouse lung tissue was frozen in liquid nitrogen after IRI 
surgery, and used in RBD pulldown assays. IRI surgery of the left lung results in RhoA activation 
whereas RhoA activity in the sham control right lung is unchanged from control mice lung.  
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Depletion of ROS attenuates TEM 
As discussed in Chapter 1, there is significant evidence that ROS are also 
involved in the processes leading to leukocyte adhesion and diapedesis. Both 
ICAM-1 and VCAM-1 have been placed upstream of ROS production in 
endothelial cells. To determine the contribution of ROS to leukocyte TEM, I 
measured the transmigration of primary human monocytes across HUVEC 
monolayers using phase video microscopy. Monocyte transmigration events 
were counted over 30 minutes, and are presented in figure 12 as the percentage 
of monocytes which underwent diapedesis. In this preliminary experiment, I 
found that pre-treatment of HUVECs with apocynin (an NADPH oxidase inhibitor) 
or allopurinol (a xanthine oxidase inhibitor) both reduced TEM. These results 
correlate with the findings of others. For example, Matheny et al. show that 
apocynin and DPI (both NADPH oxidase inhibitors) inhibit TEM of mouse splenic 
lymphocytes across monolayers of a mouse endothelial cell line [2]. As 
discussed earlier, leukocytes may also be an important source of ROS during 
adhesion and transmigration. This has been shown in the context of leukocyte 
transepithelial migration [167].  
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Figure 12. Monocyte transmigration is inhibited by treatment of HUVECs with apocynin or 
allopurinol. HUVECs were grown to confluence on matrigel coated coverslip bottom dishes, and 
treated with 10ng/ml TNF-alpha overnight. Primary human monocytes were isolated and allowed 
to adhere to HUVECs prior to beginning video microscopy. HUVECs were pre-treated with water 
(vehicle), apocynin, or allopurinol for 30 minutes prior to addition of monocytes. Transmigration 
events were counted over a period of 30 minutes. Pre-treatment of HUVECs with either apocynin 
or allopurinol inhibits monocyte transmigration. 
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ICAM-1 crosslinking results in stress fiber formation and activation of 
RhoA and Rac1 
 
There is a significant amount of literature to support the hypothesis that 
leukocyte adhesion to endothelial cells results in ROS or RNS production, and 
that this could be a potential mechanism of regulating GTPase activity. As 
discussed in chapter 1, engagement of ICAM-1 and VCAM-1 on endothelial cells 
by antibody crosslinking or leukocytes has been shown to stimulate endothelial 
ROS or RNS production. In addition, there is a significant body of work 
describing RhoA or Rac1 activation downstream of ICAM-1 or VCAM-1 
crosslinking. These papers are summarized in Table 1 below. As can be seen 
from the table, although the methods vary there is a common finding of stress 
fiber formation and either RhoA or Rac1 activation.  For example, Etienne et al. 
show that ICAM-1 crosslinking for 10 minutes induces RhoA activation as 
measured by binding of p32-labeled nucleotide [92]. Crosslinking for longer 
timepoints (30 and 60 minutes) has also been shown to result in RhoA activation 
[168], whereas others have shown that RhoA activation disappears after 30 
minutes of crosslinking with anti-ICAM1 coated beads [97].  Similar findings have 
been published for VCAM-1. For example, Cook-Mills et al. show Rac1 activation 
shortly after VCAM-1 crosslinking (30s – 2 min) which is gone by 12 minutes 
[104]. Van Wetering et al. show Rac1 activation by VCAM-1 crosslinking from 5-
15 minutes, and show that stress fibers and gaps form in the endothelial 
monolayer after 30 minutes. Interestingly, this effect is diminished in C3-
pretreated cells, indicating a role for RhoA downstream of VCAM-1. In addition to 
experiments utilizing antibody crosslinking to mimic adhesion molecule 
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clustering, there are examples of leukocyte adhesion stimulating GTPase 
activation. For example, Ishibashi et al. observed RhoA activation in primary 
human coronary microvascular ECs after 15-60 minutes of primary human 
monocyte adhesion [169]. They did not observe Rac1 activation. However, 
Ramirez et al. observed significant RhoA and Rac1 activation in primary brain 
microvascular ECs after 15 minutes of primary human monocyte adhesion [170]. 
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 Method Cell type GTPase 
Activation? 
Stress fiber/ 
Gap formation? 
Etienne et al., J 
Immunol 1998 [92] 
Crosslink 
ICAM-1 with 
soluble 
antibodies 
Immortalized 
rat brain ECs 
(RBE4) 
YES  
10’ XL ICAM-1: 
RhoA activation 
N/D 
Wojciak-Stothard et 
al., J Cell Biol 1999 
[93] 
Crosslink 
ICAM-1 with 
soluble 
antibodies 
HUVEC N/D YES – stress fibers 
30’ XL ICAM-1  
Thompson et al., J 
Immunol 2002.  
[168] 
Crosslink 
ICAM-1 with 
soluble 
antibodies 
HUVEC YES 
30’ and 60’ XL 
ICAM-1: RhoA 
Activation 
*observe a drop in 
RhoA activity with 
primary anti-ICAM 
antibody alone. 
YES – stress fibers 
60’ XL ICAM-1 
Van Wetering et al., 
Am J Physiol Cell 
Physiol 2003. 
[99] 
Crosslink 
VCAM-1 
with soluble 
antibodies 
HUVEC YES 
5’, 10’, 15’ XL 
VCAM-1: Rac1 
activation 
YES – stress fibers 
and gaps 
30’ VCAM-1 XL 
Cook-Mills et al., 
Biochem J 2004. 
[104] 
Crosslinking 
VCAM-1 
with soluble 
antibodies 
Immortalized 
mouse 
endothelial 
cell line 
(mHEVa) 
YES 
30s, 2’ XL VCAM-
1: Rac1 activation 
(gone by 12’) 
N/D 
Van Buul et al., J 
Cell Biol 2007.  [97] 
Anti-ICAM-1 
coated 
polystyrene 
beads 
HUVEC YES 
10’ XL ICAM-1: 
RhoA and Rac1 
activation (gone 
by 30’) 
N/D 
Martinelli et al., Mol 
Biol Cell 2009. [103] 
“Ligate” with 
anti-ICAM-1 
primary 
alone or 
crosslink 
with 
secondary 
Immortalized 
rat brain MV 
EC 
YES 
2’-45’ ligation with 
anti-ICAM1 ab 
alone: RhoA 
activation 
2-30’ XL ICAM-1: 
RhoA activation 
N/D 
Table 1. Summary of publications which observe RhoA and/or Rac1 activation as well as 
cytoskeletal changes in endothelial cells after ICAM-1 or VCAM-1 crosslinking (XL). ND = Not 
determined. Papers are presented in chronological order. 
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Given the evidence presented in the existing literature, we set out to ask if 
ROS are involved in the activation of RhoA downstream of ICAM-1 or VCAM-1 
signaling. To visualize ICAM-1 clustering and subsequent changes in the 
endothelial monolayer, I performed immunofluorescence experiments. TNF-
stimulated HUVECs were treated with anti-ICAM-1 antibody alone for 30 
minutes, followed by fixation in 3.7% formaldehyde solution or treated with anti-
ICAM-1 antibody for 30 minutes, washed with serum-free endothelial media, and 
treated with Alexafluor-488 conjugated goat anti-mouse secondary antibody for 
60 minutes prior to fixation. Cells that were treated with primary antibody alone 
were stained with 488-conjugated goat anti-mouse antibody post-fixation. All 
cells were stained with Texas-red conjugated phalloidin to label actin. As seen in 
figure 13A, addition of the crosslinking secondary antibody results in significant 
ICAM-1 clustering, stress fiber formation, and large gaps in the endothelial 
monolayer (asterisk). 
As described above, RhoA and Rac1 activation has been observed in 
endothelial cells after crosslinking surface cell adhesion molecules (ICAM-1 or 
VCAM-1) or after monocyte adhesion. To corroborate previously published 
findings, I performed RBD and PBD pulldowns (as described in chapter 2) after 
ICAM-1 crosslinking. ICAM-1 was crosslinked on TNF-stimulated HUVECs for 15 
minutes using soluble antibodies, and RhoA and Rac1 activity assays were 
performed. As shown in figure 13B, both RhoA and Rac1 are activated in 
response to ICAM-1 crosslinking.  
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Rac1 activation by ICAM-1 has been shown previously by Van Buul et. al 
although the focus of this work was on ICAM-1 activation of RhoG and 
subsequent apical cup assembly [97]. Rac1 activation downstream of RhoG has 
been described to occur through a complex with DOCK180 and ELMO [171]. To 
ask if RhoG is required for Rac1 activation downstream of ICAM-1, I used siRNA 
to knockdown RhoG in HUVECs followed by ICAM-1 crosslinking. Figure 13C 
shows that Rac1 is still activated, although not as robustly, in HUVECs in which 
RhoG has been knocked down. This indicates that a pathway independent of 
RhoG/DOCK180/ELMO may be involved.  
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Figure 13. ICAM-1 crosslinking results in stress fiber formation and activation of RhoA and 
Rac1. A. HUVECs were grown to confluence on matrigel coated glass coverslips and treated with 
5ng/mL TNF-alpha overnight. Cells were treated with anti-ICAM antibody for 30 minutes and fixed 
in 3.7% formaldehyde solution (1° only), or crosslinked with Alexafluor-488 conjugated goat anti-
mouse secondary for 60 minutes (1°+2°) prior to fixation. Cells that received primary antibody 
only were stained with Alexafluor-488 conjugated goat-anti mouse secondary post-fixation. All 
cells were stained with Texas red conjugated phalloidin. Crosslinking ICAM-1 results in stress 
fiber formation and gaps in the monolayer (asterisks). B. HUVECs were grown to confluence and 
treated with 5ng/ml TNF-alpha overnight. Cells were treated with anti-ICAM primary alone or 
ICAM-1 was crosslinked with goat-anti mouse secondary for 15 minutes. RBD and PBD assays 
were performed as described in chapter 2. Crosslinking ICAM-1 stimulates RhoA and Rac1 
activation. C. RhoG was knocked down in HUVECs using Oligofectamine. 48 hours post 
transfection, HUVECs were treated with TNF overnight and ICAM-1 was crosslinked as described 
above.  
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ICAM-1 crosslinking does not activate C20S RhoA 
Given our work on regulation of RhoA by ROS (presented in chapter 2), I 
wanted to ask if ICAM-1 activation of RhoA involved ROS. To do so, I used C20S 
RhoA-myc as a ROS-insensitive RhoA mutant. To show that this mutant of RhoA 
is not activated by ROS, HUVECs were infected with adenovirus to express 
either wildtype or C20S RhoA-myc, and treated with antimycin A to stimulate 
ROS production (see figure 4, Chapter 2). RhoA activity assays show that 
wildtype RhoA is significantly activated by antimycin A, whereas C20S RhoA is 
not (figure 14A). As shown in figure 14B, ICAM-1 crosslinking activates wildtype 
but not C20S RhoA, indicating a role for ROS in RhoA activation downstream of 
ICAM-1. However, as a control, I confirmed that both wildtype and C20S RhoA 
can  
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Figure 14. C20S RhoA is resistant to ROS and is not activated by ICAM-1. A. HUVECs 
expressing wildtype (wt) or C20S RhoA-myc were treated with antimycin A (AA) for 30 minutes, 
and RBD pulldown assays performed as described. AA does not activate C20S RhoA-myc. B. 
HUVECs expressing either wt or C20S RhoA-myc were stimulated with TNF, and ICAM-1 was 
crosslinked for 15 minutes using anti-ICAM coated beads. LPA treatment for 3 minutes serves as 
a positive control. Wildtype RhoA is activated by ICAM-1 crosslinking and LPA, whereas C20S 
RhoA is not. C. Quantitation of RhoA activity assays after ICAM-1 crosslinking, representative of 
2 independent experiments. 
 
 
 
 
Chapter 4: Clinical Significance and Future Directions 
Clinical Significance 
In this chapter, I will begin by discussing the clinical relevance of the work 
presented in this thesis. Two scenarios involving ROS and inflammation will be 
discussed: acute inflammation, during ischemia-reperfusion injury (IRI); and 
chronic inflammation, in the context of atherosclerosis. This discussion of clinical 
relevance will lead into topics and questions for future study. 
Ischemia-reperfusion injury (IRI) 
IRI is an acute inflammatory event which occurs when circulation is 
restored to ischemic tissues, for example, in the context of thrombosis, 
hemorrhagic shock, or organ transplantation. Although it is counter intuitive to 
consider that restoration of blood flow to an ischemic tissue could cause more 
damage, IRI has in fact been known as a serious pathological consequence of 
therapeutic intervention for quite some time. Hearse et al. were the first to show 
that reoxygenation of hypoxic rat heart resulted in further damage to the tissue 
rather than improvement [172]. Over the years, a significant effort has been 
made to understand the pathophysiology of IRI. These mechanisms include 
cellular calcium loading, acute inflammatory response, and perhaps most 
importantly the production of ROS and RNS [157]. 
Although endothelial cells have numerous mechanisms to eliminate ROS 
and RNS, during IRI these defenses are overwhelmed. This leads to increased  
vascular permeability, vessel leakage, and an acute inflammatory response 
which exacerbates and promotes further damage. The importance of ROS to the 
pathophysiology of IRI is demonstrated by in vivo studies in which ROS/RNS 
during IRI was eliminated by administration of a radical scavenger. For example, 
during lung transplant in the rat [173] or warm ischemia in the mouse [166], 
administration of N-acetyl cysteine significantly attenuated vascular injury and 
inflammation. We found similar results, using a lung hilum clamp model in the 
mouse (see Figure X). Similar findings were obtained using NADPH oxidase 
(p47phox-/-) mice or mice treated with the NADPH oxidase inhibitor apocynin 
[174].  
As discussed in Chapter 1, Rho GTPases have been shown to be critical 
players in the regulation of vascular permeability. Furthermore, inhibition of Rho 
kinase (a primary effector of RhoA) has been shown to attenuate some of the 
pathological consequences of IRI. For example, in a rat model of cardiac IRI, 
pretreatment with Y27632 prevented the cytoskeletal changes of endothelial cells 
associated with IRI [175]. A mouse model of cardiac IRI showed that inhibition of 
Rho kinase significantly reduced infarction after IRI [176]. Studies have been 
performed in other organs with similar results, with the most recent study 
showing that Y27632 reduces leukocyte infiltration in a rat model of renal IRI 
indicating a protective effect on vascular permeability and inflammation [177]. 
Given that we have shown that Rho GTPases can be activated by ROS, it 
is reasonable to propose that ROS may play a role in GTPase regulation and 
subsequent increases in vascular permeability caused by IRI. In vitro studies 
 71 
implicate ROS as a mechanism regulating Rho GTPases and changes in 
vascular permeability which occur during hypoxia and reoxygenation. Its 
important to note that hypoxia is not equivalent to ischemia, as oxygen tension 
stays high over some time in some tissues (namely the lung) despite lack of 
blood flow. Regardless, these studies provide valuable information about the 
potential role of ROS and Rho GTPases during IRI. An early paper by Lum and 
colleagues, examined bovine pulmonary microvascular endothelial cells and their 
response to hypoxia and reoxygenation [178]. They found that reoxygenation 
induced a rapid increase in vascular permeability which was associated with 
increased stress fiber formation and spindle shaped cells. They also measured 
increased ROS production during reoxygenation, and that reducing ROS 
production (by pre-treatment with SOD or catalase) attenuated the increase in 
vascular permeability. Interestingly, they found that SOD was effective only if it 
was added during hypoxia. Similarly, overexpression of SOD in human aortic 
endothelial cells was found to prevent reoxygenation-induced actin organization 
after hypoxia [179]. These results indicates that perhaps hypoxia causes a 
depletion of antioxidant enzymes (such as SOD), which are then overwhelmed 
by the ROS production which occurs during reperfusion.  
 RhoA and Rac1 activity has also been measured using pulldown assays 
(as described in Chapter 2) during hypoxia and reoxygenation [59, 180]. Wojciak-
Stothard et al. show that hypoxia results in decreased ROS production and that 
reoxygenation returns ROS levels to normoxic conditions. Furthermore, hypoxia 
resulted in decreased Rac1 activity and elevated RhoA activity. Experiments 
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using dominant negative Rac1 implicate downregulation of RhoA as downstream 
of elevated Rac1 activity. This corroborates with the Bar-Sagi pathway [57] 
described in Chapter 1. However, based on the data described in Chapter 2, we 
would expect that decreased ROS levels may result in lower levels of activity for 
both Rac1 and RhoA and that Rac1 activation may lead to RhoA activation via 
ROS. This is of course a simplistic assumption based on the data presented and 
its likely that a huge number of factors are affected when cells are exposed to 
hypoxia and reoxygenation. However, it does indicate that ROS levels during 
hypoxia/reoxygenation in vitro are regulators of Rho GTPases and that a similar 
mechanism may be occurring during IRI in vivo. 
Atherosclerosis 
Atherosclerosis is an inflammatory disease characterized by the infiltration 
of leukocytes and smooth muscle cells across the endothelium in response to the 
accumulation of pro-atherogenic factors, namely oxidized lipids. This 
accumulation of cells and lipids results in lesions within the vessel wall called 
“plaques.” Originally, it was thought that plaques consisted mainly of lipids. 
However, recruitment of monocytes to the vessel wall and subsequent 
transformation into “foam cells” was shown to be an important event preceding 
plaque formation [181]. Analysis of the cellular composition of plaques showed 
that macrophages, T cells, and smooth muscle cells were a significant 
component of plaques [182]. The identification of these cells in plaques opened 
the door to a body of work investigating the mechanisms by which cells invade 
into the endothelium during plaque formation. 
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 As expected, the cell adhesion molecules ICAM-1 and VCAM-1 have been 
shown to be an important component of atherosclerotic plaque formation. 
Selectins have also been shown to be important for plaque formation, however, 
they will not be discussed here.  
 Atherosclerosis is known to occur preferentially at sites of arterial 
branching or curvature where there is turbulent blood flow. This is likely due to 
two main factors, the first being that lipids tend to accumulate at these sites. 
Secondly, EC expression of cell adhesion molecules such as ICAM-1 and 
VCAM-1 has also been shown to be upregulated in regions of turbulent flow and 
shear stress. This likely contributes significantly to the development of plaques in 
these regions. Both ICAM-1 and VCAM-1 have been shown to be expressed on 
ECs in atherosclerotic plaques in vivo [183, 184]. In vitro experiments show that 
the accumulation of oxidized lipid enhances the expression of cell adhesion 
molecules in activated ECs [185]. Importantly, in rabbits fed an atherogenic diet, 
the expression of VCAM-1 occurs very early, much before the first appearance of 
neointimal macrophages [186, 187]. This indicates that ICAM-1 and VCAM-1 are 
likely upstream of the inflammatory events which mediate atherogenesis, rather 
than their elevated expression being a consequence of monocyte recruitment.  
 A number of studies using knockout animals have shown the importance 
of cell adhesion molecules to plaque formation. ICAM-null animals on either a 
standard C57Bl/6 background or ApoE-/- background have been shown to have 
reduced plaque formation [188, 189]. Results seem to highly depend on the 
timepoint at which the animals are studied and the diet the animals are fed. 
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Bourdillon et al. found reduced plaque formation in ICAM-null animals at all 
timepoints studied (6-20 weeks) if the animals were fed a standard “chow” diet 
[190]. However, the absence of ICAM was not protective at early (6 weeks) or 
late timepoints (20 weeks) if the animals were fed a high-fat atherogenic diet. 
VCAM-1 null animals have also been studied and found to have a significant 
reduction in plaque formation [191]. Interestingly, Cybulsky and colleagues did 
not find that ICAM deficiency was atheroprotective.  
 The role of ROS in atherogenesis has focused largely on the contribution 
of oxidized lipids to plaque formation. Leukocytes at the site of plaque formation 
generate ROS which further oxidizes LDL into highly oxidized LDL, which in turn 
is taken up by macrophages to form foam cells. These foam cells become 
embedded into the vessel wall and promote further plaque formation by secretion 
of growth factors, which attracts more leukocytes and smooth muscles to 
perpetuate this process.  In vitro experiments have shown that expression of 
NADPH oxidase is upregulated under conditions of turbulence or oscillatory 
shear stress, which is pro-atherogenenic [192]. The opposite is true under 
conditions of laminar shear stress which is atheroprotective. In vivo, deletion of 
NADPH oxidase (p47phox -/-) has been shown to protect mice from development 
of plaques when in a hypercholesterolemic background (apoE -/-) [193]. These 
mice also had significantly reduced production of aortic ROS production. A study 
of atherosclerotic human coronary arteries showed that ROS production was 
enhanced and that oxidized LDL is spatially associated with a subunit of the 
NADPH oxidase complex (p22phox) [194]. Furthermore, a number of vasoactive 
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factors which are known to generate ROS/RNS such as angiotensin II, thrombin, 
and TNF have been found in human atherosclerotic plaques.  
 It is tempting to speculate that ROS production during the development of 
atherosclerotic plaques could involved regulation of Rho GTPases. As described 
throughout this thesis, Rho GTPases regulate vascular permeability and 
leukocyte transendothelial migration through their actions on the cytoskeleton. 
These processes are both highly involved in the pathogenesis of atherosclerosis. 
In addition to their role as modulators of the cytoskeleton and endothelial barrier 
function, Rho GTPases may have a role in activation of endothelial cells during 
the early stages of atherosclerosis. 
Hypoxia and reoxygenation and the resulting production of ROS has been 
shown to stimulate expression of VCAM-1 [195]. Importantly, this is abolished in 
cells expressing dominant negative Rac1, indicating Rac1 is upstream of VCAM-
1 expression. Rac1 is also implicated in the enhanced expression of cell 
adhesion molecules when cells are stimulated with TNF alpha [196] or when cells 
are subjected to shear stress [197]. Both of these situations involve elevated 
ROS production and Rac1 activation. The common link between all of these 
studies is likely to be Rac1’s important role as an upstream activator of NF-kB, 
which is known to promote the activation of a multitude of genes involved in the 
inflammatory response including ICAM-1 and VCAM-1 [198, 199]. RhoA has also 
been associated with increased expression of cell adhesion molecules in studies 
using thrombin, a well studied activator of RhoA/Rho kinase and NF-kB [200].  
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Future Directions 
Understanding the mechanisms which regulate leukocyte transmigration is 
critical to developing therapies for the large number of pathological situations 
which involve inflammation. In this thesis, I have presented preliminary evidence 
for a potential pathway involving regulation of Rho GTPases by ROS during 
leukocyte TEM. This hypothesis is based on findings presented in Chapter 2, in 
which we showed that ROS can directly regulate the GTPase RhoA and that this 
mechanism of regulation requires the presence of two cysteine residues in RhoA. 
In the preliminary work presented in Chapter 3, I have shown that ICAM-1 
activation stimulates RhoA and Rac1, and that C20S myc-RhoA is resistant to 
ICAM-1 activation. This indicates that ROS may potentially be involved in RhoA 
activation after ICAM-1 engagement. 
 In future work, it will be critical to determine the role of ROS in mediating 
TEM and whether regulation of RhoA by ROS has a role in TEM. In figure 12, I 
have shown that inhibiting ROS production in endothelial cells inhibits the 
transmigration of monocytes. This result is preliminary, but is in agreement with 
the findings of others who have shown that inhibiting either ROS or RNS in 
endothelial cells results in decreased leukocyte TEM [103, 201]. These 
experiments need to be repeated. Inhibitor studies have caveats due to the non-
specific nature of many inhibitors used to inactivate ROS/RNS producing 
enzymes. However, these studies, if carefully controlled, can provide useful 
information on the sources of ROS/RNS involved in TEM. It would also be useful 
to measure ROS/RNS production in endothelial cells upon leukocyte adhesion. I 
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have attempted these experiments, however, I have had great difficulty due to 
the sensitive nature of the dyes used. A large number of oxidation sensitive dyes 
are available to test, which greatly increases the likelihood of successfully 
measuring ROS production in ECs after leukocyte adhesion.  
In addition to inhibitor studies and measurement of ROS production, a 
critical experiment is to measure leukocyte TEM across endothelial monolayers 
which express either wildtype or ROS-resistant C20S myc-RhoA. If our 
hypothesis is correct, expression of C20S RhoA will reduce leukocyte TEM. 
These experiments would have to be carefully controlled to show that expression 
of C20S RhoA does not affect leukocyte adhesion or ICAM-1 clustering, as RhoA 
has been shown to be involved in the expression and function of cell adhesion 
molecules [202]. 
 In addition to TEM experiments utilizing endothelial cells expressing 
wildtype or C20S RhoA, it will important to do GTPase activation assays after 
leukocyte adhesion. These experiments can be difficult given the potent 
proteases present in many leukocytes. Using high concentrations of protease 
inhibitors during lysis and increasing the amount of GST proteins used for 
pulldown assays (thereby decreasing the incubation time) should reduce 
proteolysis of proteins. Experiments utilizing leukocyte adhesion are also 
valuable in that they provide insight into whether ICAM-1, VCAM-1, or both cell 
adhesion molecules are involved in RhoA activation and potentially ROS 
activation of RhoA. This can be achieved in experiments comparing the response 
of endothelial cells to the adhesion of granulocytic leukocytes (which primarily 
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use ICAM-1) versus monocytic leukocytes (which use both ICAM-1 and VCAM-
1). Similar experiments can be performed using blocking antibodies to block 
either ICAM-1 or VCAM-1. VCAM-1 has been shown to be present in “cups” 
which surround transmigrating leukocytes [101] and that Rac1 activation 
downstream of VCAM-1 results in ROS production which is required for TEM 
[201]. It will interesting to repeat crosslinking experiments using anti-VCAM-1 
antibody, and measure Rac1 and RhoA activation.  
 In addition to identifying a role for ROS, and regulation of RhoA by ROS 
during TEM, it will be important to investigate the mechanisms of ROS production 
in ECs after leukocyte adhesion via ICAM-1 or VCAM-1. A critical experiment is 
the use of ICAM-1 or VCAM-1 truncated mutants in which the cytoplasmic tail 
has been deleted. Experiments using truncated mutants of ICAM-1 have shown 
that the cytoplasmic tail is important for RhoA activation [203]; ICAM-1 
localization and cup assembly [204]; and leukocyte transmigration [85, 205]. 
Using adenovirus to express either GFP-tagged full length or cytoplasmic tail 
deleted ICAM-1 would allow us to ask if ICAM-1’s cytoplasmic tail is required for 
ROS production, Rac1 and RhoA activation, stress fiber formation, and increased 
permeability.   
 As described above, VCAM-1 activation has been shown to result in Rac1 
activation, NADPH oxidase activation and ROS production. In preliminary data, I 
have shown that ICAM-1 can activate Rac1 (figure 13). ICAM-1 engagement has 
been shown to result in ROS production through xanthine oxidase [206] and 
NOS production through iNOS [103]. Given the existing literature on VCAM-1, it 
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is plausible to consider the hypothesis that ICAM-1 activation may also result in 
ROS production through Rac1 NADPH oxidase. Given our laboratory’s expertise 
in identification of GEFs, it would be feasible to also identify GEFs downstream of 
ICAM-1 activation leading to Rac1 activation and NADPH oxidase activation. It 
may be the case that both ICAM-1 and VCAM-1 can activate Rac1 but only 
VCAM-1 results in NADPH oxidase activation. This would be a perfect example 
of the critical importance of localization to ROS signaling. Although both cell 
adhesion molecules can activate Rac1, only signals derived from one signaling 
cascade, presumably mediated through unique binding partners and scaffolding 
proteins, result in NADPH oxidase activation. This has been shown for S1P and 
VEGF. Both growth factors potently activate Rac1, however, only VEGF results 
in ROS production via NADPH oxidase in endothelial cells [49]. Should this be 
the case for ICAM-1 and VCAM-1, investigating the unique molecular players 
involved would be an interesting and important direction for future research.  
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Appendix 
In this appendix, I describe experiments and approaches which I have 
attempted. I present a brief summary of the approach, potential issues with these 
experiments and possibilities for future study. 
Mass spectrometry/proteomics approaches 
The identification of cysteine oxidative modification in Rho GTPases is a 
critical component of this project. In describing the mechanism for redox-
mediated Rho GTPase regulation, Sharon Campbell’s group obtained and 
published mass spectrometry results showing chemical intermediates and 
oxidative modification (disulfide bond formation) [63, 64].  I attempted to identify 
cysteine modifications of RhoA, immunoprecipitated from cells using two 
methods. The first method, is a brute force mass spectrometry approach in which 
RhoA was expressed in Hela cells or fibroblasts as a myc-tagged protein, and 
immunoprecipitated after treatment of cells with media alone or media containing 
hydrogen peroxide. A high, non-physiological level of peroxide was used (1-
5mM) to attempt to form an irreversible oxidative modification. Due to a variety of 
logistical and technical issues, I was not able to obtain reproducible data with this 
approach. The second approach is a biochemical approach in which oxidized 
cysteines in proteins are biotinylated. This technique has a number of variations 
[207-209]. Common to all techniques is the general approach involving three 
steps: (1) blocking of free thiols (cysteines) (2) reduction of oxidized cysteines (3) 
labeling of newly formed cysteines. A diagram of this general procedure is shown 
in Figure 15A, using S-nitrosylation as an example. In Figure 15B, I present a 
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preliminary experiment in which cells were treated with an NO donor, SNAP, 
followed by the oxidized-cysteine labeling protocol. In this preliminary 
experiment, RhoA appears to be nitrosylated although the specific residue was 
not identified. An appropriate next step would be repeating this procedure with 
cysteine to alanine RhoA mutants. In collaboration with Aaron Hobbs from the 
Campbell lab and Rob Dekroon from the Systems proteomics facility (Oscar 
Alzate), we have attempted to identify oxidative modifications using purified 
recombinant RhoA GTPase. Our approach essentially follows the procedure 
outlined above, with the exception that blocking of free thiols in step 1 and 
labeling of newly formed thiols after reduction (step 3) both utilize fluorescent-
tagged probes. This allows independent measurement of “free cystienes” and 
“oxidized cysteines” providing a quantitative measure of the extent of cysteine 
oxidation. These studies to date have proved to be difficult, with a variety of 
factors causing protein degradation or denaturation and unintended oxidation. 
This remains a work-in-progress. 
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Figure 15. Labeling oxidizing cysteines. A. General approach to labeling oxidized cysteines 
beginning with (1) blocking of free cysteines with iodoacetic acid or other irreversible thiol reacting 
compound (2) reduction of oxidized cysteines (3) labeling of newly formed free cysteines with 
biotin or fluorophore-tagged thiol reacting compound. B. Hela cells expressing RhoA-myc were 
subjected to the cysteine labeling procedure using iodoacetic to block free cysteines and DTT to 
reduce oxidized cysteines, followed by labeling with biotin. Streptavidin beads were used to 
isolate biotinylated proteins and the isolated sample was blotted with anti-myc antibody. 
Treatment of cells with SNAP (an NO donor) resulted in detection of cysteine oxidation of RhoA-
myc. 
 
 83 
Intravital microscopy 
 
Visualization of leukocyte-endothelial interactions is critical to our understanding 
of the basic mechanisms of leukocyte transmigration and inflammation. 
Advances in mouse models and microscopy make intravital microscopy more 
accessible now than ever before. Many of the intravital studies in this field have 
used a cremaster model. Although this model is well characterized and used 
frequently, it requires significant technical and surgical skill as well as specialized 
preparation of the microscope stage. In preliminary studies, I have utilized a 
mouse dermal model of inflammation using the mouse ear. This approach is 
much more straightforward than the cremaster model, and can be performed on 
any confocal microscope with a heated stage. One disadvantage of this model is 
the inability to directly inject cytokine (for example TNF-alpha) into the tissue, as 
the mouse ear is simply too thin. As an alternative, acute dermal inflammation 
can be stimulated with a topical irritant, for example croton oil. There are multiple 
methods available for visualizing leukocytes. A transgenic mouse can be used 
which expresses GFP on specific leukocyte types. For example, the Cx3cr1 
mouse from Jackson labs expresses EGFP on monocytes, dendritic cells, and 
natural killer cells. One can also directly inject fluorophore-conjugated antibodies 
against leukocyte markers. This would allow tagging of specific leukocyte types 
(for example monocytes vs neutrophils), but has the disadvantage that it is quite 
expensive given the expense of antibodies and the relatively large quantities of 
antibody used per experiment. The last approach is the simplest, and involves 
injection of a dye which labels all intravascular cells with mitochrondria. This dye, 
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Rhodamine 6G, is readily available and inexpensive. Although this approach is 
straightforward, it does have the disadvantage that it is non-specific for any 
leukocyte in the bloodstream. In addition to labeling leukocytes, it is 
advantageous to label the vascular space. Injection of fluorescently labeled 
dextran is commonly used, although transgenic animals or fluorophore-
conjugated antibodies can also be used. In figure 16, I present two images from 
an intravital imaging experiment demonstrating the ability to visualize the 
vascular space and leukocytes in vivo using a mouse ear model. All of these 
experiments are performed under an authorized IACUC protocol #10-210.0 . 
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Figure 16. Examples of intravital microscopy using a mouse ear model. A. Leukocytes were 
labeled in vivo with Rhodamine 6G via tail vein injection and visualized in the mouse ear using a 
25X water objective. B. The vascular space is visualized using Rhodamine-dextran injected via 
tail vein.  
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Experiments with leukocytes 
 
An important part of this project is to translate experimental results from antibody 
crosslinking experiments to physiologically relevant experiments using 
leukocytes as the stimulus for endothelial signaling events. However, this 
approach poses a multitude of complications for biochemistry experiments. The 
first, is that leukocytes interact with endothelial cells with a variety of different cell 
adhesion molecules. This results in an array of different signaling events, and 
significantly complicates analysis of results from biochemistry experiments. Not 
all leukocytes and leukocyte cell lines adhere to endothelial cells via the same 
adhesion molecules, therefore, this can be used to delineate which adhesion 
molecules are involved with a given signaling pathway. The second problem with 
using leukocytes is that they express potent proteases. This was a significant 
source of frustration for this project, as I found that leukocyte proteases caused 
significant degradation of endothelial proteins. Figure 16 shows total levels of 
VE-cadherin and PECAM (both endothelial proteins) when lysed in the presence 
of increasing amounts of THP-1 cells in SDS containing sample buffer. Its 
important to note that this effect was not dependent on adhesion, and occurred 
when leukocytes were simply mixed with endothelial lysates. This can be dealt 
with by lightly fixing leukocytes [210]. This approach is commonly used but does 
pose issues with using a physiologically irrelevant stimulus. As shown in Figure 
16, lightly fixing leukocytes prior to combining them with endothelial cells 
prevents endothelial protein degradation. The second approach is to adjust 
experimental methods such that they can be performed more quickly, and also 
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pre-treatment of leukocytes with high doses of protease inhibitors prior to 
experiments. I have not tried this approach.  
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Figure 17. THP cells result in degradation of EC proteins. EC’s were mixed with THP cells in 
either a 1:1 or 1:5 ratio and lysed in sample buffer containing 2% SDS, 50mM DTT, and 5% BME. 
THP cells were left non-fixed or fixed gently with 2% paraformaldehyde and washed extensively. 
The total cell lysates were blotted for endothelial specific markers, VE-cadherin and PECAM. 
THP cells cause a significant reduction in VE-cadherin and PECAM levels when not fixed, 
however, this effect is abrogated when THP cells are fixed indicating a likely role for leukocyte 
proteases.  
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Rac1/SOD1 interaction 
 
Feedback loops are hypothesized to be important components of redox-mediated 
signaling pathways, as they are in many other signaling pathways. These 
pathways can work in multiple ways, for example by coupling ROS/RNS 
producing enzymes with ROS/RNS scavenging enzymes through a common 
factor. A recent study demonstrates the interaction of Rac1 and superoxide 
dismutase (SOD1), and proposes a model in which the interaction between Rac1 
and SOD1 serves as a “redox sensor” [159]. They propose that under reducing 
conditions, Rac1-GTP and SOD1 interact and that SOD1 stabilizes the active 
GTP-bound Rac1. This drives ROS production through NADPH oxidase. The 
localized accumulation of ROS, specifically hydrogen peroxide through 
spontaneous or SOD1-driven dismutation, leads to dissociation of SOD1 from 
Rac1. This dissociation promotes GTP hydrolysis to GDP, Rac1 inactivation, and 
presumably shuts down NADPH oxidase activity. 
 To explore the interaction between Rac1 and SOD1 we have generated 
several tools. We have generated GST-tagged SOD1 to use in pulldown assays, 
in which we ask if different cellular treatments promote or inhibit endogenous 
Rac1 association with SOD1. For example, does Rac1 activation by for example 
EGF stimulate Rac1’s association with SOD1. Does alteration of cellular redox 
state, either by exogenous or endogenous ROS or RNS, affect Rac1’s 
association with SOD1? We have also generated myc-tagged wildtype, C18A, 
and C18S Rac1. These proteins can be expressed in cells, and used to ask if the 
redox-state of Rac1 affects its binding to SOD1. For example, does activation of 
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Rac1 by ROS promote its binding to SOD1 and is this effect abolished with 
redox-insensitive C18A or C18S Rac1? In a preliminary experiment, I have been 
able to confirm that endogenous Rac1 can be pulled out of cell lysates with GST-
SOD1. However, no change was observed when cells were treated with peroxide 
to oxidize Rac1 or when cells were treated with EGF to activate Rac1. Due to 
time constraints, I was not able to further pursue these experiments.  
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